脳神経内科診断ハンドブック　改訂2版

出版社： 中外医学社
著者：
発行日： 2024-03-20
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784498328792
電子書籍版： 2024-03-20 （2版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

多岐にわたる疾患について，最新のガイドライン・診断基準・重症度分類に準拠し必要な知識を1冊で！日常診療で役立つ，各疾患の基本的事項，診断基準使用のコツ，臨床亜型，今後の課題を考えるうえで役に立つ診断基準の問題点をわかりやすく解説適切な診断と治療のための必須知識をまとめた診察室に常備したいマニュアル．

目次

  • A　脳死─成人・小児
    B　脳血管障害
    C　認知症
    D　運動異常症
    E　脊髄小脳変性症
    F　運動ニューロン疾患
    G　感染症，炎症性疾患
    H　脱髄性疾患，非感染性炎症性疾患
    I　代謝性疾患
    J　傍腫瘍性症候群
    K　てんかんと類縁疾患
    L　頭痛
    M　睡眠疾患
    N　脊椎・脊髄疾患
    O　末梢神経疾患
    P　自律神経疾患
    Q　神経筋接合部疾患
    R　筋ジストロフィー
    S　筋炎・ミオパチー
    T　ミトコンドリア病
    U　白質ジストロフィー
    V　血管炎症候群
    W　内科疾患に伴う神経障害，その他

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

A 脳死 - 成人・小児

P.11 掲載の参考文献
1) 厚生科学研究費特別研究事業 脳死に関する研究班 昭和60年度研究報告書. 脳死の判定指針および判定基準. 日医雑誌. 1985 ; 94 : 1949-72.
 
2) 厚生省厚生科学研究費特別研究事業「脳死判定手順に関する研究班」平成11年度報告書. 法的脳死判定マニュアル. 1999.
 
3) 公益社団法人日本臓器移植ネットワーク. http://www.jotnw.or.jp/jotnw/law_manual/pdf/noushi-hantei.pdf
 
4) 脳死判定基準のマニュアル化に関する研究班. 厚生労働科学研究費補助金厚生労働科学特別研究事業「臓器提供施設における院内体制整備に関する研究」法的脳死判定マニュアル (平成22年度). 2011.
 
5) 永山正雄. 脳死. 脳科学辞典. 日本神経科学学会・脳科学関連学会連合 脳科学辞典編集委員会. 2021. https://bsd.neuroinf.jp/wiki/脳死
 
6) A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. JAMA. 1968 ; 205 : 337-40.
 
7) 古俣めぐみ. 日本における「脳死人の死」規定とその根拠-二つの社会的合意からの分析. 東京大学教養学部哲学・科学史部会. 哲学・科学史論叢. 2017 ; 19 : 73-95.
 
8) President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Defining death. Washington DC : Government Printing Office ; 1981.
 
9) Guidelines for the determination of death. Report of the medical consultants on the diagnosis of death to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. JAMA. 1981 ; 246 : 2184-6.
 
10) Practice parameters for determining brain death in adults (summary statement). The Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1995 ; 45 : 1012-4.
 
11) An appraisal of the criteria of cerebral death. A summary statement. A collaborative study. JAMA. 1977 ; 237 : 982-6.
PubMed
12) Diagnosis of brain death. Statement issued by the honorary secretary of the Conference of Medical Royal Colleges and their Faculties in the United Kingdom on 11 October 1976. Br Med J. 1976 ; 2 : 1187-8.
PubMed
13) Pallis C. ABC of brain stem death. Reappraising death. Br Med J (Clin Res Ed). 1982 ; 285 : 1409-12.
PubMed
14) Robbins NM, Bernat JL. Practice Current : When do you order ancillary tests to determine brain death? Neurol Clin Pract. 2018 ; 8 : 266-74.
 
15) Wijdicks EF, Varelas PN, Gronseth GS, et al ; American Academy of Neurology. Evidence-based guideline update : determining brain death in adults : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 ; 74 : 1911-8.
 
16) 竹内一夫. 厚生省厚生科学研究費特別研究事業「脳死に関する研究班」. 昭和59年度報告書. 日本医事新報. 1985 ; 3188 : 112-4.
 
17) 園生雅弘, 宮地洋輔, 著. 永山正雄, 監修. 脳死状態. 今日の臨床サポート. https://clinicalsup.jp/jpoc/ContentPage.aspx?DiseaseID93&SearchTermすべて&SearchText脳死-GUIDELINE
 
18) 厚生労働科学研究費補助金研究班主任研究者 横田裕行, 監修. 臓器提供ハンドブック. 東京 : へるす出版 ; 2019.
 
19) 日本救急医学会脳死・臓器組織移植に関する委員会. 脳死判定における補助検査について. https://www.jaam.jp/info/2015/info-20150529.html
 
20) 園生雅弘. モノグラフ「臨床脳波を基礎から学ぶ人のために」No.21 脳死. 臨床神経生理. 2008 ; 36 : 47-55.
 
21) Greer DM, Shemie SD, Lewis A, et al. Determination of Brain Death/Death by Neurologic Criteria : The World Brain Death Project. JAMA. 2020 ; 324 : 1078-97.
PubMed
22) Silverman D, Saunders MG, Schwab RS, Masland RL. Cerebral death and the electroencephalogram. Report of the ad hoc committee of the American Electroencephalographic Society on EEG Criteria for determination of cerebral death. JAMA. 1969 ; 209 : 1505-10.
 
23) Braksick SA, Robinson CP, Gronseth GS, et al. Variability in reported physician practices for brain death determination. Neurology. 2019 ; 92 : e888-94.
PubMed
24) 永山正雄. 脳死判定とCritical Care Neurology. 脳死・脳蘇生. 2016 ; 28 : 91-7.
 
25) Greer DM. Determination of Brain Death. N Engl J Med. 2021 ; 385 : 2554-61.
PubMed
26) Brigham and Women's Hospital COVID-19 Clinical Guidelines. 2020. https://covidprotocols.org/
 
27) Addendum to Emory Healthcare's Brain Death Determination Policy effective 04/17/2020. https://www.emoryhealthcare.org/ui/pdfs/covid/medical-professionals/BrainDeathTestingintheSettingofCOVID-19.pdf
 
28) Migdady I, Rae-Grant A, Greer DM. Brain death evaluation during the pandemic. Neurology. 2020 ; 95 : 693-4.
PubMed
29) 教皇庁科学アカデミー, 著. 上智大学生命倫理研究所, 監訳. 死のしるし 脳死と臓器移植に関する教皇庁のワークショップ. 上智大学出版 ; 2021.
 
30) 日本弁護士連合会. 臨時脳死及び臓器移植調査会「答申」に対する意見書. 1992.
 
31) Shewmon DA. Chronic "brain death" : meta-analysis and conseptual consequences. Neurology. 1998 ; 51 : 1538-45.
 
32) 寺岡慧, 横田裕行, 永山正雄, 町野 朔. わが国における脳死を巡る論争の経緯. In : 教皇庁科学アカデミー教皇庁科学アカデミー, 著. 上智大学生命倫理研究所, 監訳. 死のしるし 脳死と臓器移植に関する教皇庁のワークショップ. 上智大学出版 ; 2021.
 
33) Omelianchuk A, Bernat J, Caplan A, et al. Revise the Uniform Determination of Deaath Act to Align the Law With Practice Through Neurorespiratory Criteria. Neurology. 2022 ; 98 : 532-6.
PubMed
34) Greer DM, Kirschen MP, Lewis A, et al. Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline. Neurology. 2023 ; 101 : 1112-32.
PubMed
35) Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline : Report of the AAN Guidelines Subcommittee, AAP, CNS, and SCCM. Neurology. 2024 ; 102 : e208108.
PubMed

B 脳血管障害

P.23 掲載の参考文献
1) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke. 1990 ; 21 : 637-76.
PubMed
2) Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 ; 24 : 35-41.
 
3) Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994 ; 25 : 2220-6.
 
4) Gotoh F, Terayama Y, Amano T ; Stroke Scale Committee of the Japan Stroke Society. Development of a novel, weighted, quantifiable stroke scale : Japan stroke scale. Stroke. 2001 ; 32 : 1800-7.
PubMed
5) 日本脳卒中学会. TIA定義について. https://www.jsts.gr.jp/img/tiateigi_201910.pdf.
 
6) Ay H, Furie KL, Singhal A, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005 ; 58 : 688-97.
PubMed
7) Adams HP Jr. Clinical scales to assess patients with stroke. In : Grotta JC, Albers GW, Broderick JP, et al. editors. Stroke, pathophysiology, diagnosis, and management. 6th ed. 2016. p.308-25.
 
8) 橋本洋一郎, 伊藤康幸. 潜因性脳卒中の診断手順. 脳卒中. 2016 ; 38 : 434-41.
Medical*Online
9) Trousseau A : Phlegmasia alba dolens. Clin Med Hotel Dieu De Paris. 1865 ; 3 : 94.
 
10) 内山真一郎. トルーソー症候群. 日内会誌. 2008 ; 97 : 45-8.
 
11) 野川茂. がんと脳梗塞-トルーソー症候群の臨床. 血栓止血誌. 2016 ; 27 : 18-28.
 
12) Okazaki S, Morimoto T, Kamatani Y, et al. Moyamoya disease susceptibility variant RNF213 p.R4810K increases the risk of ischemic stroke attributable to large-artery atherosclerosis. Circulation. 2019 ; 139 : 295-8.
PubMed
13) Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke : the Causative Classification of Stroke System. Stroke. 2007 ; 38 : 2979-84.
PubMed
14) Amarenco P, Bogousslavsky J, Caplan LR, et al. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). Cerebrovasc Dis. 2013 ; 36 : 1-5.
PubMed
15) van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 ; 19 : 604-7.
 
16) 篠原幸人, 峰松一夫, 天野隆弘, 他. modified Rankin Scaleの信頼性に関する研究-日本語版判定基準書および問診表の紹介. 脳卒中. 2007 ; 29 : 6-13.
 
17) Shinohara Y, Minematsu K, Amano T, et al. Modified Rankin Scale with expanded guidance scheme and interview questionnaire : Interrater agreement and reproducibility of assessment. Cerevrovasc Dis. 2006 ; 21 : 271-8.
PubMed
P.31 掲載の参考文献
1) Mizuta I, Watanabe-Hosomi A, Koizumi T, et al. New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy in Japan. J Neurol Sci. 2017 ; 381 : 62-7.
PubMed
2) 難病情報センター. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 (CADASIL) (指定難病124). https://www.nanbyou.or.jp/entry/4445. Accessed April 29, 2020.
 
3) Onodera O, Nozaki H, Fukutake T. HTRA1 Disorder [online]. 2019. https://www.ncbi.nlm.nih.gov/books/NBK32533/. Accessed April 29, 2020.
 
4) 難病情報センター. 禿頭と変形性脊椎症を伴う常染色体劣性白質脳症 (指定難病123). https://www.nanbyou.or.jp/entry/4550. Accessed April 29, 2020.
 
5) 小児慢性特定疾病情報センター. 診断の手引き ファブリー (Fabry) 病. https://www.shouman.jp/disease/instructions/08_06_091/. Accessed April 29, 2020.
 
6) 水野敏樹, 水田依久子. 遺伝性脳小血管病のトピックス. 医学の歩み. 2017 ; 262 : 199-204.
 
7) Uemura, M. et al. High frequency of HTRAI AND ABCC6 mutations in Japanese patients with adult-onset cerebral small vessel disease. J Neurol Neurosurg Psychiatry. 2023 ; 94 : 74-81.
PubMed
8) Verdura E, Herve D, Scharrer E, et al. Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease. Brain. 2015 ; 138 : 2347-58.
PubMed
9) Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease-recommendations of a European expert group. J Inherit Metab Dis. 2011 ; 34 : 509-14.
 
10) 猪原匡史. Fabry 病の診断と治療. 神経治療. 2019 ; 36 : 140-4.
Medical*Online
11) Rutten JW, Dauwerse HG, Gravesteijn G, et al. Archetypal NOTCH3 mutations frequent in public exome : implications for CADASIL. Ann Clin Transl Neurol. 2016 ; 3 : 844-53.
PubMed
12) Okada T, Washida K, Irie K, et al. Prevalence and atypical clinical characteristics of NOTCH3 mutations among patients admitted for acute lacunar infarctions. Front Aging Neurosci. Epub 2020.
 
13) Pantoni L. Cerebral small vessel disease : from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010 ; 9 : 689-701.
PubMed
14) Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke. 1995 ; 26 : 1293-301.
PubMed
15) Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996 ; 383 : 707-10.
PubMed
16) Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med. 2009 ; 360 : 1729-39.
PubMed
17) Moody DM, Brown WR, Challa VR, et al. Periventricular venous collagenosis : association with leukoaraiosis. Radiology. 1995 ; 194 : 469-76.
PubMed
18) Staals J, Booth T, Morris Z, et al. Total MRI load of cerebral small vessel disease and cognitive ability in older people. Neurobiol Aging. 2015 ; 36 : 2806-11
 
19) Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023 ; 22 : 602-18.
PubMed
P.37 掲載の参考文献
1) Lyden P. Using the National Institutes of Health Stroke Scale : A cautionary tale. Stroke. 2017 ; 48 : 513-9.
 
2) 日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン 2021. 東京 : 協和企画 ; 2021.
 
3) Li N, Wang Y, Wang W, et al. Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage : a prospective study of 139 cases. Stroke. 2011 ; 42 : 3441-6.
 
4) Orito K, Hirohata M, Nakamura Y, et al. Leakage sign for primary intracerebral hemorrhage : A novel predictor of hematoma growth. Stroke. 2016 ; 47 : 958-63.
PubMed
5) Boulouis G, Morotti A, Charidimou A, et al. Noncontrast computed tomography markers of intracerebral hemorrhage expansion. Stroke. 2017 ; 48 : 1120-5.
PubMed
6) Sakuta K, Sato T, Komatsu T, et al. The NAG scale : Noble predictive scale for hematoma expansion in intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2018 ; 27 : 2606-12.
PubMed
7) Yogendrakumar V, Moores M, Sikora L, et al. Evaluating hematoma expansion scores in acute spontaneous intracerebral hemorrhage : a systematic scoping review. Stroke. 2020 ; 51 : 1305-8.
PubMed
8) Law ZK, Ali A, Krishnan K, et al. Noncontrast computed tomography signs as predictors of hematoma expansion, clinical outcome, and response to tranexamic acid in acute intracerebral hemorrhage. Stroke. 2020 ; 51 : 121-8.
PubMed
9) Gladstone DJ, Aviv RI, Demchuk AM, et al. Effect of recombinant activated coagulation factor VII on hemorrhage expansion among patients with spot sign-positive acute intracerebral hemorrhage : The SPOTLIGHT and STOP-IT Randomized Clinical Trials. JAMA Neurol. 2019 ; 76 : 1493-501.
PubMed
10) Connolly ES Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 ; 43 : 1711-37.
PubMed
11) Hunt WE, Kosnik EJ. Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg. 1974 ; 21 : 79-89.
PubMed
12) Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg. 1988 ; 68 : 985-6.
PubMed
13) Mule S, Soize S, Benaissa A, et al. Detection of aneurysmal subarachnoid hemorrhage 3 months after initial bleeding : evaluation of T2* and FLAIR MR sequences at 3 T in comparison with initial non-enhanced CT as a gold standard. J Neurointerv Surg. 2016 ; 8 : 813-8.
 
14) Kowalski RG, Claassen J, Kreiter KT, et al. Initial misdiagnosis and outcome after subarachnoid hemorrhage. JAMA. 2004 ; 291 : 866-9.
PubMed
15) Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968 ; 28 : 14-20.
PubMed
P.43 掲載の参考文献
1) Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010 ; 74 : 1346-50.
PubMed
2) Chung KK, Anderson NE, Hutchinson D, et al. Cerebral amyloid angiopathy related inflammation : three case reports and a review. J Neurol Neurosurg Psychiatry. 2011 ; 82 : 20-6.
 
3) Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 2008 ; 18 : 253-66.
PubMed
4) Knudsen KA, Rosand J, Karluk D, et al. Clinical diagnosis of cerebral amyloid angiopathy : validation of the Boston criteria. Neurology. 2001 ; 56 : 537-9.
PubMed
5) Hirohata M, Yoshita M, Ishida C, et al. Clinical features of non-hypertensive lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Eur J Neurol. 2010 ; 17 : 823-9.
PubMed
6) 関島良樹. 脳アミロイド血管症. 精神科治療学. 2019 ; 34 : 274-6.
 
7) Charidimou A, Law R, Werring DJ. Amyloid "spells" trouble. Lancet. 2012 ; 380 : 1620.
PubMed
8) Yamada M, Itoh Y, Suematsu N, et al. Vascular variant of Alzheimer's disease characterized by severe plaque-like beta protein angiopathy. Dement Geriatr Cogn Disord. 1997 ; 8 : 163-8.
PubMed
P.47 掲載の参考文献
1) 黒田敏, 藤村幹, 高橋淳, 他. 厚生労働省科学研究費補助金難治性疾患克服事業もやもや病 (ウイリス動脈輪閉塞症) における難病の医療水準の向上や患者のQOL向上に資する研究班. もやもや病診断基準 2021年改訂版 (解説). 脳卒中の外科. 2022 ; 50 : 1-7.
 
2) Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011 ; 56 : 34-40.
 
3) Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969. 20 : 288-99.
PubMed
4) Zhang J, Li.S, Fujimura M. Hemodynamic analysis of the recipient parasylvian cortical arteries for predicting postoperative hyperperfusion during STA-MCA bypass in adult patients with moyamoya disease. J Neurosurgery. (in press).
 
5) Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G > A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012 ; 78 : 803-10.
PubMed
6) Houkin K, Nakayama N, Kuroda S, et al. Novel magnetic resonance angiography stage grading for moyamoya disease. Cerebrovasc Dis. 2005 ; 20 : 347-54.
PubMed
7) Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke. 2014 ; 45 : 1415-21.
PubMed
8) Takahashi JC, Funaki T, Houkin K, et al. Significance of the hemorrhagic site for recurrent bleeding : prespecified analysis in the Japan Adult Moyamoya Trial. Stroke. 2016 ; 47 : 37-43.
PubMed
P.49 掲載の参考文献
1) Hart RG, Diener HC, Coutts SB, et al. Embolic stroke of undetermined source : the case for a new clinical construct. Lancet Neurol. 2014 ; 13 : 429-38.
PubMed
P.52 掲載の参考文献
1) 矢坂正弘. 大動脈原性脳梗塞の病態, 診断, 予防に関する研究. 成冨博章, 編. 循環器病研究委託費による研究18 公-2「粥状硬化性機序による難治性脳梗塞の診断, 治療, 予防に関する研究」平成20年度報告書.
 
2) Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994 ; 331 : 1474-9.
PubMed
3) Amarenco P, Duyckaerts C, Tzourio C, et al. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med. 1992 ; 326 : 221-5.
PubMed
4) The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med. 1996 ; 334 : 1216-21.
PubMed
5) Fujimoto S, Yasaka M, Otsubo R, et al. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke. 2004 ; 35 : 1426-9.
PubMed
6) Di Tullio MR, Russo C, Jin Z, et al. Aortic arch plaques and risk of recurrent stroke and death. Stroke. 2009 ; 119 : 2376-82.
PubMed
7) Ueno Y, Kimura K, Iguchi Y, et al. Mobile aortic plaques are a cause of multiple brain infarcts seen on diffusion-weighted imaging. Stroke. 2007 ; 38 : 2470-6.
PubMed
8) Sen S, Hinderliter A, Sen PK, et al. Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. Circulation. 2007 ; 116 : 928-35.
PubMed
9) Ueno Y, Yamashiro K, Tanaka R, et al. Emerging risk factors for recurrent vascular events in patients with embolic stroke of undetermined source. Stroke. 2016 ; 47 : 2714-21.
PubMed
10) Fujimoto S, Toyoda K, Jinnouchi J, et al. Difference in diffusion-weighted image and transesophageal echocardiographical findings in cardiogenic, paradoxical and aortogenic brain embolism. Cerebrovasc Dis. 2011 ; 32 : 148-54.
PubMed
P.56 掲載の参考文献
1) 日本脳卒中学会, 日本循環器学会, 日本心血管インターベンション治療学会. 潜因性脳梗塞に対する経皮的卵円孔開存閉鎖術の手引き 第2版. 脳卒中. 2023 ; 45 : 511-37.
Medical*Online
2) Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013 ; 81 : 619-25.
PubMed
3) Di Tullio MR, Sacco RL, Sciacca RR, et al. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. Am J Coll Cardiol. 2007 ; 49 : 797-802.
 
4) Lensing AWA, et al. Diagnosis of venous thrombosis. Hemostasis and thrombosis : basic principles and clinical practice. Philadelphia : JB Lippincott ; 1993. p.1297-321.
 
5) Ljungqvist M, Soderberg M, Moritz P, et al. Evaluation of wells score and repeated D-dimer in diagnosing venous thromboembolism. Eur J Intern Med. 2008 ; 19 : 285-88.
 
6) 神田直昭, 矢坂正弘, 大坪亮一, 他. 虚血性脳血管障害における右左シャントおよび心房中隔瘤の意義 : コントラスト経食道心エコー図による検討. 臨床神経. 1998 ; 38 : 213-8.
 
7) Homma S, Di Tullio MR, Sacco RL, et al. Age as determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke. 2004 ; 35 : 2145-9.
PubMed
P.61 掲載の参考文献
1) Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012 ; 11 : 906-17.
PubMed
2) Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 ; 334 : 494-500.
 
3) Casey SO, Sampaio RC, Michel E, et al. Posterior reversible encephalopathy syndrome : utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000 ; 21 : 1199-206.
PubMed
4) Calabrese LH, Dodick DW, Schwedt TJ, et al. Narrative review : reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007 ; 146 : 34-44.
PubMed
P.66 掲載の参考文献
1) Hosoya T, Adachi M, Yamaguchi K, et al. Clinical and neuroradiological features of intracranial vertebrobasilar artery dissection. Stroke. 1999 ; 30 : 1083-90.
PubMed
2) 細矢貴亮. 診断「診断基準と診断の手引き」. In : 松岡秀樹, 他編. 脳動脈解離診断の手引き. 大阪 : 国立循環器病センター ; 2009. p.20-30.
 
P.70 掲載の参考文献
1) Masuhr F, Mehraein S, Einhaupl K. Cerebral venous and sinus thrombosis. J Neurol. 2004 ; 251 : 11-23.
PubMed
2) See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021 ; 325 : 2448-56.
PubMed

C 認知症

P.76 掲載の参考文献
1) McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 ; 7 : 263-9.
PubMed
2) 日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕, 監訳. DSM-5 : DSM-5 精神疾患の診断・統計マニュアル. 東京 : 医学書院 ; 2014.
 
3) Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease : the IWG-2 criteria. Lancet Neurol. 2014 ; 13 : 614-29.
PubMed
4) McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 ; 34 : 939-44.
PubMed
5) Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 ; 7 : 270-9.
 
6) Sperling RA, Aisen PS, Becket LA, et al. Toward defining the preclinical stages of Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 ; 7 : 280-92.
 
7) Sakane N, Josephs KA, Litvan I, et al. Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimers Dement. 2019 ; 15 : 1218-28.
 
8) Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework : Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 ; 14 : 535-62.
 
P.80 掲載の参考文献
1) 「特発性正常圧水頭症診療ガイドライン作成に関する研究」班, 日本正常圧水頭症学会. 特発性正常圧水頭症診療ガイドライン. 第3版. 大阪 : メディカルレビュー社 ; 2020.
 
2) Hashimoto M, Ishikawa M, Mori E, et al. Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme : a prospective cohort study. Cerebrospinal Fluid Res. 2010 ; 7 : 18.
PubMed
3) Marmarou A, Young HF, Aygok GA, et al. Diagnosis and management of idiopathic normal-pressure hydrocephalus : a prospective study in 151 patients. J Neurosurg. 2005 ; 102 : 987-97.
PubMed
4) Yamada S, Ishikawa M, Yamamoto K. Comparison of CSF distribution between idiopathic normal pressure hydrocephalus and Alzheimer Disease. AJNR Am J Neuroradiol. 2016 ; 37 : 1249-55.
PubMed
5) Yamada S, Ishikawa M, Miyajima M, et al. Timed up and go test at tap test and shunt surgery in idiopathic normal pressure hydrocephalus. Neurol Clin Pract. 2017 ; 7 : 98-108.
PubMed
P.85 掲載の参考文献
1) Katz DI, Bernick C, Dodick DW, et al. National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for traumatic encephalopathy syndrome. Neurology. 2021 ; 96 : 848-63.
PubMed
2) McKee AC, Cairns NJ, Dickson DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathologica. 2016 ; 131 : 75-86.
PubMed
3) Martland HS. Punch drunk. JAMA. 1928 ; 91 : 1103-7.
 
4) Parker HL. Traumatic encephalopathy ('punch drunk') of professional pugilists. J Neurol Psychopathol. 1934 ; 15 : 20-8.
PubMed
5) Omalu BI, DeKosky ST, Minster RL, et al. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005 ; 57 : 128-34.
 
6) Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med. 1973 ; 3 : 270-303
 
7) McKee AC Robert CC, Christopher J, et al. Chronic traumatic encephalopathy in athletes : progressive tauopathy following repetitive head injury. Neuropathol Exp Neurol. 2009 ; 68 : 709-35
 
8) Montenigro PH, Baugh CM, Daneshvar DH, et al. Clinical subtypes of chronic traumatic encephalopathy : literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers ResTher. 2014 ; 6 : 68.
PubMed
P.94 掲載の参考文献
1) McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology. 2017 ; 89 : 88-100.
PubMed
2) Goldman JG, Forsberg LK, Boeve BF, et al. Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimers Res Ther. 2020 ; 12 : 137.
PubMed
3) 橋本衛, 眞鍋雄太, 森 悦朗, 他. 認知機能変動評価尺度の内容妥当性と評価者間信頼性の検討. Brain Nerve. 2014 ; 66 : 175-83.
 
4) Miyamoto T, Miyamoto M, Iwanami M, et al. The REM sleep behavior disorder screening questionnaire : validation study of a Japanese version. Sleep Med. 2009 ; 10 : 1151-4.
PubMed
5) https://www.lbda.org
 
6) Fujiwara Y, Suzuki H, Yasunaga M, et al. Brief screening tool for mild cognitive impairment in older Japanese : validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int. 2010 ; 10 : 225-32.
PubMed
7) Thomas AJ, Taylor JP, McKeith I, et al. Revision of assessment toolkits for improving the diagnosis of Lewy body dementia : the DIAMOND Lewy study. Int J Geriatr Psychiatry. 2018 ; 33 : 1293-304.
PubMed
8) Keezer MR, Wolfson C, Postuma RB. Age, gender, comorbidity, and the MDS-UPDRS : Results from a population-based study. Neuroepidemiology. 2016 ; 46 : 222-7.
PubMed
9) Choi H, Ha S, Im HJ, et al. Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging. Neuroimage Clin. 2017 ; 16 : 586-94.
PubMed
10) Orimo S, Yogo M, Nakamura T, et al. (123) I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev. 2016 ; 30 : 122-33.
 
11) Kaufmann H, Norcliffe-Kaufmann L, et al. Natural history of pure autonomic failure : A United States prospective cohort. Ann Neurol. 2017 ; 81 : 287-97.
PubMed
12) Morenas-Rodriguez E, Sala I, Subirana A, et al. Clinical subtypes of dementia with Lewy bodies based on the initial clinical presentation. J Alzheimers Dis. 2018 ; 64 : 505-13.
PubMed
13) O'Dowd S, Schumacher J, Burn DJ, et al. Fluctuating cognition in the Lewy body dementias. Brain. 2019 ; 142 : 3338-50.
PubMed
14) Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies : a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 ; 9 : 969-77.
PubMed
15) Goldman JG, Forsberg LK, Boeve BF, et al. Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimers Res Ther. 2020 ; 12 : 137.
PubMed
P.103 掲載の参考文献
1) Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011 ; 134 : 2456-77.
PubMed
2) Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011 ; 76 : 1006-14.
PubMed
3) Knopman DS, Kramer JH, Boeve BF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008 ; 131 : 2957-68.
PubMed
4) Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015 ; 386 : 1672-82.
PubMed
5) Fukuhara R, Ghosh A, Fuh JL, et al. Family history of frontotemporal lobar degeneration in Asia--an international multi-center research. Int Psychogeriatr. 2014 ; 26 : 1967-71.
PubMed
6) Ogura A, Watanabe H, Kawabata K, et al Semantic deficits in ALS related to right lingual/fusiform gyrus network involvement. EBioMedicine. 2019 ; 47 : 506-17.
PubMed
7) Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017 ; 140 : 3329-45.
PubMed
8) 桝田道人, 渡辺宏久, 勝野雅央, 他. FTLD-Jからみたわが国における前頭側頭型認知症の臨床特徴. 老年精神医学雑誌. 2019 ; 30 : 1107-13
 
9) Lamarre AK, Rascovsky K, Bostrom A, et al. Interrater reliability of the new criteria for behavioral variant frontotemporal dementia. Neurology. 2013 ; 80 : 1973-7.
PubMed
10) Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020 ; 26 : 387-97.
PubMed
11) Panza F, Lozupone M, Seripa D, et al. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. 2020 ; 16 : 213-28.
PubMed
12) Lennox RD, Wolfe RN. Revision of the self-monitoring scale. J Personal Soc Psychol. 1984 ; 46 : 1349-64.
PubMed
13) Toller G, Ranasinghe K, Cobigo Y, et al. Revised Self-Monitoring Scale : A potential endpoint for frontotemporal dementia clinical trials. Neurology. 2020 ; 94 : e2384-95.
 
14) Trieu C, Gossink F, Stek ML, et al. Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia : a systematic review. Cogn Behav Neurol. 2020 ; 33 : 1-15.
PubMed
P.110 掲載の参考文献
1) Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia : diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993 ; 43 : 250-60.
PubMed
2) Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 ; 42 : 2672-713.
PubMed
3) Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment : Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2018 ; 14 : 280-92.
PubMed
4) Hachinski VC, Bowler JV. Vascular dementia. Neurology. 1993 ; 43 : 2159-60.
PubMed
5) 日本神経学会, 監修. 認知症疾患診療ガイドライン 2017. 東京 : 医学書院 ; 2017. p.309-10.
 
6) Chung KK, Anderson NE, Hutchinson D, et al. Cerebral amyloid angiopathy related inflammation : three case report and a review. J Neurol Neurosurg Psychiatry. 2011 ; 82 : 20-6.
 
7) Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017 ; 140 : 1829-50.
PubMed
8) Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy : a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022 ; 21 : 714-25.
PubMed
9) Pescini F, Nannucci S, Bertaccini B, et al. The cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) scale : a screening tool to select patients for NOTCH3 gene analysis. Stroke. 2012 ; 43 : 2871-6.
 
10) Koizumi T, Mizuta I, Watanabe-Hosomi A, et al. The CADASIL Scale-J, A modified scale to prioritize access to genetic testing for Japanese CADASIL-suspected patients. J Stroke Cerebrovasc Dis. 2019 ; 28 : 1431-9.
 

D 運動異常症

P.116 掲載の参考文献
1) Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 ; 30 : 1591-9.
PubMed
2) Berg D, Adler CH, Bloem BR, et al. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord. 2018 ; 33 : 1643-6.
PubMed
3) Goetz CG, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : scale presentation and clinimetric testing results. Mov Disord. 2007 ; 22 : 41-7.
PubMed
4) Hoehn MM, Yahr M. Parkinsonism : onset, progression and mortality. Neurology. 1967 ; 17 : 427-42.
PubMed
5) Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease : results from an international pilot study. Mov Disord. 2007 ; 22 : 1901-11.
PubMed
6) Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995 ; 4 : 241-8.
 
7) Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 ; 51 : 745-52.
 
8) Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 ; 55 : 181-4.
 
9) 「パーキンソン病診療ガイドライン」作成委員会. パーキンソン病診療ガイドライン 2018. 東京 : 医学書院 ; 2018.
 
10) Postuma RB, Poewe W, Litvan I, et al. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 ; 33 : 1601-8.
PubMed
P.131 掲載の参考文献
1) Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord. 2017 ; 32 : 853-64.
PubMed
2) Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007 ; 130 : 1552-65.
PubMed
3) 神経変性疾患領域における基盤的調査研究班ホームページ. http://plaza.umin.ac.jp/neuro2/representative/index.html
 
4) Ali F, Martin PR, Botha H, et al. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord. 2019 ; 34 : 1144-53.
PubMed
5) Shimohata T, Kanazawa M, Takahashi H, et al. Diagnostic criteria for progressive supranuclear palsy with predominant cerebellar ataxia. Mov Disord. 2015 ; 30 (Supple 1) : 847
 
6) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olzewski syndrome) : Report of the NINDS-SPSP interenational workshop. Neurology. 1996 ; 47 : 1-9.
 
7) Grimm MJ, Respondek G, Stamelou M, et al. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord. 2019 ; 34 : 1228-32.
PubMed
8) MDS-PSP基準に基づいた進行性核上性麻痺の診断補助ツール (PSP Dx Assist). (https://psp-assist.com/)
 
9) Shimohata T, Kanazawa M, Yoshida M, et al. Clinical and imaging findings of progressive supranuclear palsy with predominant cerebellar ataxia. Mov Disord. 2016 ; 31 : 760-2.
PubMed
P.135 掲載の参考文献
1) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 ; 80 : 496-503.
PubMed
2) 下畑享良, 饗場郁子, 西澤正豊. 大脳皮質基底核症候群と大脳皮質基底核変性症の診断. 臨床神経. 2016 ; 56 : 149-57.
 
3) Lang A, Stebbins G, Boxer A. The Corticobasal Degeneration Functional Rating Scale (CBD-FS) [abstract]. Mov Disord. 2017 ; 32 (suppl 2).
 
4) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndromre : a comparative study. J Neurol Neurosurg Psychiatry. 2012 ; 83 : 405-10.
 
5) Ouchi H, Toyoshima Y, Tada M, et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord. 2014 ; 29 : 238-44.
PubMed
6) Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 2014 ; 85 : 925-9.
PubMed
7) Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord. 2017 ; 32 : 853-64.
PubMed
P.142 掲載の参考文献
1) Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018 ; 33 : 7-87.
 
2) Elble R, Comella C, Fahn S, et al. Reliability of a new scale for essential tremor. Mov Disord. 2012 ; 27 : 1567-9.
PubMed
3) Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord. 1998 ; 13 (Suppl 3) : 2-23.
 
4) Sun QY, Xu Q, Tian Y, et al. Expansion of GGC repeat in the human-specific NOTCH2NLC gene is associated with essential tremor. Brain. 2020 ; 43 : 222-33.
 
5) Louis ED, Bares M, Benito-Leon J, et al. Essential tremor-plus : a controversial new concept. Lancet Neurol. 2020 ; 19 : 266-70.
 
6) Fahn S, Tolosa E, Conceppcion M. Clinical rating scale for tremor. In : Jankovic J, Tolosa E, editors. Parkinson's Disease and Movement Disorders. Baltimore, MD : Williams and Wilkins ; 1993. p.271-80.
 
7) Ondo W, Hashem V, LeWitt PA, et al. Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale. Mov Disord Clin Pract. 2017 23 ; 5 : 60-5.
 
P.147 掲載の参考文献
1) 難病情報センター. ハンチントン病 (指定難病8). https://www.nanbyou.or.jp/entry/318 (2024年1月アクセス)
 
2) 難病情報センター. 神経有棘赤血球症 (指定難病9). https://www.nanbyou.or.jp/entry/4052 (2024年1月アクセス)
 
3) Huntington Study Group. Unified Huntington's Disease Rating Scale : reliability and consistency. Mov Disord. 1996 ; 11 : 136-42.
 
4) 佐野輝, 中村雅之, 新井 薫, 他. 神経有棘赤血球症 診療の手引き. 平成29年度厚生労働科学研究費補助金 難治性疾患等政策研究事業「神経変性疾患領域における基盤的調査研究」班. 2017.
 
5) The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993 ; 72 : 971-83.
 
6) Ueno S, Maruki K, Nakamura M, et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet. 2001 ; 28 : 121-2.
 
7) Rampoldi L, Dobson-Stone C, Rubio JP, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet. 2001 ; 28 : 119-20.
 
8) Ho M, Chelly J, Carter JN, et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell. 1994 ; 77 : 869-80.
 
9) Nishida Y, Nakamura M, Urata Y, et al. Novel pathogenic VPS13A gene mutations in Japanese patients with chorea-acanthocytosis. Neurol Genet. 2019 ; 5 : e332.
PubMed
10) Urata Y, Nakamura M, Sasaki N, et al. Novel pathogenic XK mutations in McLeod syndrome and interaction between XK protein and chorein. Neurol Genet. 2019 ; 5 : e328.
PubMed
P.151 掲載の参考文献
1) Manyam BV. What is and what is not 'Fahr's disease'. Parkinsonism Relat Disord. 2005 ; 11 : 73-8.
 
2) Fahr VT. Idiopatische Verkalkung der Hirmgefaesse. Centralblatt fur Allgemeine Pathologie u. Pathogische Anatomie. 1930 ; 50 : 129-33.
 
3) Sobrido MJ, Coppolla G, Oliveira J, et al. Primary familial brain calcification. NCBI Bookshelf [online]. https://www.ncbi.nlm.nih.gov/books/NBK1421/, last update : August 24, 2017.
 
4) Wang C, Li Y, Shi L, et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet. 2012 ; 44 : 254-6.
 
5) Nicolas G, Pottier C, Maltete D, et al. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology. 2013 ; 80 : 181-7.
PubMed
6) Keller A, Westenberger A, Sobrido MJ, et al. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet. 2013 ; 45 : 1077-82.
PubMed
7) Legati A, Giovannini D, Nicolas G, et al. Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. Nat Genet. 2015 ; 47 : 579-81.
PubMed
8) Yao XP, Cheng X, Wang C, et al. Biallelic mutations in MYORG cause autosomal recessive primary familial brain calcification. Neuron. 2018 ; 98 : 1116-23.
PubMed
9) Cen Z, Chen Y, Chen S, et al. Biallelic loss-of-function mutations in JAM2 cause primary familial brain calcification. Brain. 2020 : 143 : 491-502.
 
10) 山田恵, 田中真生, 高木まり, 他. 本邦における特発性基底核石灰化症の臨床的・遺伝学的検討. 臨床神経. 2014 ; 54 (Suppl) : S66
 
11) Kurita H. Ozawa K, Yamada M, et al. Evaluation of headaches in primary brain calcification in Japan. Neurol Clin Neurosci. 2021 ; 9 : 419-505.
 
12) Takeuchi T, Aoyagi H, Kuwako Y, et al. Evaluation of headaches in primary brain calcification in Japan. PLoS One. 2022 : 17 : e0275227.
 
13) 山田恵, 保住功. 特発性基底核石灰化症 (いわゆる 'Fahr病') の異常運動. 脳神経内科. 2020 ; 92 : 56-62.
 
14) Livingston JH, Stivaros S, Warren D, et al. Intracranial calcification in childhood : a review of aetiologies and recognizable phenotypes. Dev Med Child Neurol. 2014 ; 56 : 612-26.
PubMed
15) Kosaka K. Diffuse neurofibrillary tangles with calcification : a new presenile dementia. J Neurol Neurosurg Psychiatry. 1994 ; 57 : 594-6.
PubMed
16) Ukai K, Kosaka K. Diffuse neurofibrillary tangles with calcification (Kosaka-Shibayama disease) in Japan. Psychiatry Clin Neurosci. 2016 ; 70 : 131-40.
PubMed
17) Cunha J, Oliveira J. Challenging the concept of diffuse neurofibrillary tangles with calcification (Kosaka-Shibayama disease). Psychiatry and Clin Neurosci. 2017 ; 71 : 70.
 
18) Hozumi I, Kurita H, Ozawa K, et al. Inorganic phosphorus (Pi) in CSF is a biomarker for SLC20A2-associated idiopathic basal ganglia calcification (IBGC1). J Neurol Sci. 2018 ; 388 : 150-4.
PubMed
P.156 掲載の参考文献
1) Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011 ; 18 : 5-18.
PubMed
2) Carding PN, Horsley IA, Docherty GJ. A study of the effectiveness of voice therapy in the treatment of 45 patients with nonorganic dysphonia. J Voice. 1999 ; 13 : 72-104.
PubMed
3) Comella CL, Leurgans S, Wuu J, et al. Rating scales for dystonia : a multicenter assessment. Mov Disord. 2003 ; 18 : 303-12.
PubMed
4) Comella CL, Stebbins GT, Goetz CG, et al. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord. 1997 ; 12 : 570-5.
PubMed
5) Jankovic J, Kenney C, Grafe S, et al. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 ; 24 : 407-13.
PubMed
6) Merz RI, Deakin J, Hawthorne MR. Oromandibular dystonia questionnaire (OMDQ-25) : a valid and reliable instrument for measuring health-related quality of life. Clin Otolaryngol. 2010 ; 35 : 390-6.
PubMed
7) Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index (VHI) : development and validation. Am J Speech-Lang Pathol. 1997 ; 6 : 66-70.
 
8) Muller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24) : development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry. 2004 ; 75 : 749-53.
PubMed
9) Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord. 1997 ; 12 : 100-2.
PubMed
10) 「ジストニア診療ガイドライン」作成委員会, 編集. 日本神経学会, 監修. ジストニア診療ガイドライン 2018. 東京 : 南江堂 ; 2018.
 
P.160 掲載の参考文献
1) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth edition (DSM-5). American Psychiatric Association. Arlington 2013.
 
2) Parees I, Kojovic M, Pires C, et al. Physical precipitating factors in functional movement disorders. J Neurol Sci. 2014 ; 338 : 174-7.
PubMed
3) Thomas M, Jankovic J. Psychogenic movement disorders : diagnosis and management. CNS Drugs. 2004 ; 18 : 437-52.
PubMed
4) Kim YJ, Pakiam AS, Lang AE. Historical and clinical features of psychogenic tremor : a review of 70 cases. Can J Neurol Sci. 1999 ; 26 : 190-5.
PubMed
5) Lang AE. Psychogenic dystonia : a review of 18 cases. Can J Neurol Sci. 1995 ; 22 : 136-43.
PubMed
6) Monday K, Jankovic J. Psychogenic myoclonus. Neurology. 1993 ; 43 : 349-52.
PubMed
7) Okun MS, Koehler PJ. Paul Blocq and (psychogenic) astasia abasia. Mov Disord. 2007 ; 22 : 1373-8.
PubMed
8) Thenganatt MA, Jankovic J. Psychogenic (functional) parkinsonism. Handb Clin Neurol. 2016 ; 139 : 259-62.
PubMed
9) Hallett M. Psychogenic parkinsonism. J Neurol Sci. 2011 ; 310 : 163-5.
PubMed
10) Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010 ; 81 : 5-12.
PubMed
11) Schrag A, Trimble M, Quinn N, et al. The syndrome of fixed dystonia : an evaluation of 103 patients. Brain. 2004 ; 127 : 2360-72.
PubMed
12) Brown P, Rothwell JC, Thompson PD, et al. The hyperekplexias and their relationship to the normal startle reflex. Brain. 1991 ; 114 : 1903-28.
 
13) Schwingenschuh P, Katschnig P, Seiler S, et al. Moving toward "laboratory-supported" criteria for psychogenic tremor. Mov Disord. 2011 ; 26 : 2509-15.
PubMed
14) Thompson PD, Colebatch JG, Brown P, et al. Voluntary stimulus-sensitive jerks and jumps mimicking myoclonus or pathological startle syndromes. Mov Disord. 1992 ; 7 : 257-62.
PubMed
15) Hinson VK, Cubo E, Comella CL, et al. Rating scale for psychogenic movement disorders : scale development and clinimetric testing. Mov Disord. 2005 ; 20 : 1592-7.
PubMed
16) Nielsen G, Ricciardi L, Meppelink AM, et al. A Simplified Version of the Psychogenic Movement Disorders Rating Scale : The Simplified Functional Movement Disorders Rating Scale (S-FMDRS). Mov Disord Clin Pract. 2017 ; 4 : 710-6.
 

E 脊髄小脳変性症

P.167 掲載の参考文献
1) Pellerin D, Danzi MC, Wilke C, et al. Deep Intronic FGF14 GAA repeat expansion in late-onset cerebellar ataxia. N Eng J Med. 2023 ; 388 : 128-41.
 
2) Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the Assessment and Rating of Ataxia : Development of a new clinical scale. Neurology. 2006 ; 66 : 1717-20.
PubMed
3) 佐藤和則, 矢部一郎, 相馬広幸, 他. 新しい小脳性運動失調の重症度評価スケールScale for the Assessment and Rating of Ataxia (SARA) 日本語版の信頼性に関する検討. BRAIN and NERVE. 2009 ; 61 : 591-5.
 
4) Shirai S, Yabe I, Matsushima M, et al. Quantitative evaluation of gait ataxia by accelerometers. J Neurol Sci. 2015 ; 358 ; 253-8.
PubMed
5) Shirai S, Yabe I, Takahashi-Iwata I, et al. The responsiveness of triaxial accelerometer measurement of gait ataxia is higher than that of the Scale for the Assessment and Rating of Ataxia in the early stages of spinocerebellar ataxia. Cerebellum. 2019 ; 18 ; 721-30.
PubMed
6) Hashimoto Y, Honda T, Matsumura K, et al. Quantitative evaluation of human cerebellum-dependent motor learning through prism adaptation of hand-reaching movement. PLoS One. 2015 ; 10 : e0119376.
PubMed
P.172 掲載の参考文献
1) Palau F, Espinos C. Autosomal recessive cerebellar ataxias. Orphanet J Rare Dis. 2006 ; 1 : 47.
PubMed
2) Koenig M. Rare forms of autosomal recessive neurodegenerative ataxia. Semin Pediatr Neurol. 2003 ; 10 : 183-92.
PubMed
3) De Michele G, Coppola G, Cocozza S, et al. A pathogenetic classification of hereditary ataxias : is the time ripe? J Neurol. 2004 ; 251 : 913-22.
PubMed
4) Tsuji S, Onodera O, Goto J, Nishizawa M, Study Group on Ataxic D. Sporadic ataxias in Japan--a population-based epidemiological study. Cerebellum. 2008 ; 7 : 189-97.
 
5) Cortese A, Simone R, Sullivan R, et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat Genet. 2019 ; 51 : 649-58.
PubMed
6) Miyatake S, Yoshida K, Koshimizu E, et al. Repeat conformation heterogeneity in cerebellar ataxia, neuropathy, vestibular areflexia syndrome. Brain. 2022 ; 145 : 1139-50.
PubMed
7) Tsuchiya M, Nan H, Koh K, et al. RFC1 repeat expansion in Japanese patients with late-onset cerebellar ataxia. J Hum Genet. 2020 ; 65 : 1143-7.
PubMed
8) Scriba CK, Beecroft SJ, Clayton JS, et al. A novel RFC1 repeat motif (ACAGG) in two Asia-Pacific CANVAS families. Brain. 2020 ; 143 : 2904-10.
 
9) Yuan JH, Higuchi Y, Ando M, et al. Multi-type RFC1 repeat expansions as the most common cause of hereditary sensory and autonomic neuropathy. Front Neurol. 2022 ; 13 : 986504.
PubMed
10) Szmulewicz DJ, Roberts L, McLean CA, et al. Proposed diagnostic criteria for cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS). Neurol Clin Pract. 2016 ; 6 : 61-8.
PubMed
11) Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome : molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003 ; 72 : 869-78.
PubMed
12) Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome : clinical features, genetics, and testing guidelines. Mov Disord. 2007 ; 22 : 2018-30, quiz 2140.
PubMed
13) Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997 ; 145 : 205-11.
PubMed
14) Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia : development of a new clinical scale. Neurology. 2006 ; 66 : 1717-20.
PubMed
P.181 掲載の参考文献
1) Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008 ; 71 : 670-6.
PubMed
2) Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022 ; 37 : 1131-48.
PubMed
3) Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004 ; 19 : 1391-402.
 
4) Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999 ; 163 : 94-8.
PubMed
5) Osaki Y, Ben-Shlomo Y, Lees AJ, et al. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord. 2009 ; 24 : 2272-6.
PubMed
6) Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy an analysis of 230 Japanese patients. Brain. 2002 ; 125 : 1070-83.
PubMed
7) Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy : a position statement by the Neuropsychology Task Force of the MDS multiple system atrophy (MODIMSA) Study Group. Mov Disord. 2014 ; 29 : 857-67.
 
8) Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic REM sleep behavior disorder : a multicenter study. Ann Neurol. 2015 ; 77 : 830-9.
PubMed
9) Yoshida K, Kuwabara S, Nakamura K, et al. Idiopathic cerebellar ataxia (IDCA) : diagnostic criteria and clinical analyses of 63 Japanese patients. J Neurol Sci. 2018 ; 384 : 30-5.
PubMed
10) Trouillas P, Takayanagi T, Hallett M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci. 1997 ; 145 : 205-11.
PubMed
11) Schmitz-Hubsch T, Tezenas du Montcel S, Baliko L, et al. Scale for the assessment and rating of ataxia : development of a new clinical scale. Neurology. 2006 ; 66 : 1717-20.
 
12) Tsuji S, Onodera O, Goto J, et al. Sporadic ataxias in Japan -a population-based epidemiological study. Cerebellum. 2008 ; 7 : 189-97.
PubMed
13) Burk K, Globas C, Wahl T, et al. MRI-based volumetric differentiation of sporadic cerebellar ataxia. Brain. 2004 ; 127 : 175-81.
PubMed
14) Burk K, Buhring U, Schulz JB, et al. Clinical and magnetic resonance imaging characteristics of sporadic cerebellar ataxia. Arch Neurol. 2005 ; 62 : 981-5.
PubMed
15) Abele M, Burk K, Schols L, et al. The aetiology of sporadic adult-onset ataxia. Brain. 2002 ; 125 : 961-8.
PubMed
16) Abele M, Minnerop M, Urbach H, et al. Sporadic adult onset ataxia of unknown etiology : a clinical, electrophysiological and imaging study. J Neurol. 2007 ; 254 : 1384-9.
PubMed
17) Jacobi H, Rakowicz M, Rola R, et al. Inventory of non-ataxia signs (INAS) : validation of a new clinical assessment instrument. Cerebellum. 2013 ; 12 : 418-28.
PubMed
P.188 掲載の参考文献
1) 瀧山嘉久, 三輪道然, 高紀信, 他. 痙性対麻痺の診断基準の提案. 厚生労働省難治性疾患等克服研究事業, 運動失調症の病態解明と治療法開発に関する研究班 平成25年度研究報告書. 2014. p.87-90.
 
2) Schule R, Holland-Letz T, Kimpre S, et al. The Spastic Paraplegia Rating Scale (SPRS) : a reliable and valid measure of disease severity. Neurology. 2006 ; 67 : 430-4.
PubMed
3) 日本神経学会・厚生労働省 運動失調症の医療基盤に関する調査委員会, 監修. 脊髄小脳変性症・多系統萎縮症診療ガイドライン作成委員会, 編集. 脊髄小脳変性症・多系統萎縮症診療ガイドライン 2018. 東京 : 南江堂 ; 2018. p.95-118.
 
4) https://neuromuscular.wustl.edu/spinal/fsp.html
 
5) Harding AE. Hereditary "pure" spastic paraplegia : a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry. 1981 ; 44 : 871-83.
PubMed
6) 瀧山嘉久, 三輪道然, 高紀信, 他. 痙性対麻痺診断基準案の妥当性の検討. 厚生労働省難治性疾患等克服研究事業, 運動失調症の病態解明と治療法開発に関する研究班 平成26年度研究報告書. 2015. p.29-31.
 
7) http://www.nanbyou.or.jp
 
8) McDermott CJ, Shaw PJ. Hereditary spastic paraplegia. In : Eisen AA and Shaw PJ, editors. Handbook of Clinical Neurology. Vol 82. Motor neuron disorders and related diseases. Amsterdam ; Elsevier Science : 2007. p.198-211.
 
9) Koh K, Ishiura H, Tsuji S, et al. JASPAC : Japan Spastic Paraplegia Research Consortium. Brain Sci. 2018 ; 8 : 153.
 
10) Meseguer-Henarejos AB, Sanchez-Meca J, Lopez-Pina JA, et al. Inter- and intra-rater reliability of the Modified Ashworth Scale : a systematic review and meta-analysis. Eur J Phys Rehabil Med. 2018 ; 54 : 576-90.
 

F 運動ニューロン疾患

P.195 掲載の参考文献
1) Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited : World Federation of Neurology Research Group on Motor Neuron Diseases. Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 ; 1 : 293-9.
 
2) Geevasinga N, Loy CT, Menon P, et al. Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis : A systematic review using individual patient data. Clin Neurophysiol. 2016 ; 127 : 2684-91.
PubMed
3) Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020 ; 131 : 1975-8.
PubMed
4) 日本神経学会「筋萎縮性側索硬化症診療ガイドライン」作成委員会. 筋萎縮性側索硬化症診療ガイドライン 2013. https://www.neurology-jp.org/guidelinem/als2013_index.html
 
5) 難病情報センター 筋萎縮性側索硬化症. https://www.nanbyou.or.jp/entry/214
 
6) Balendra R, Al Khleifat A, Fang T, et al. A standard operating procedure for King's ALS clinical staging. Amyotroph Lateral Scler Front Degener. 2019 ; 20 : 159-64.
 
7) Chio A, Hammond ER, Mora G, et al. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015 ; 86 : 38-44.
PubMed
8) Hannaford A, Pavey N, van den Bos M, et al. Diagnostic utility of Gold Coast criteria in amyotrophic lateral sclerosis. Ann Neurol. 2021 ; 89 : 979-86.
PubMed
9) Otani R, Shibuya K, Shimizu T, et al. Diagnostic utility of Gold Coast criteria for amyotrophic lateral sclerosis in Asia. Amyotroph Lateral Scler Frontotemporal Degener. 2024 ; 1-7.
PubMed
10) Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994 ; 124 (SUPPL.) : 96-107.
 
11) de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008 ; 119 : 497-503.
PubMed
12) Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, et al. Diagnostic criteria for amyotrophic lateral sclerosis : A multicentre study of inter-rater variation and sensitivity. Clin Neurophysiol. 2019 ; 130 : 307-14.
PubMed
13) 日本神経学会. ALS治療ガイドライン 2002. https://neurology-jp.org/guidelinem/pdf/als_01.pdf
 
14) 日本神経学会. 筋萎縮性側索硬化症診療ガイドライン 2013. 東京 : 南江堂 ; 2013.
 
P.200 掲載の参考文献
1) Byrne S, Bede P, Elamin M, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 ; 12 : 157-9.
PubMed
2) Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis : what do we really know? Nat Rev Neurol. 2011 ; 7 : 603-15.
PubMed
3) Naruse H, Ishiura H, Mitsui J, et al. Molecular epidemiological study of familial amyotrophic lateral sclerosis in Japanese population by whole-exome sequencing and identification of novel HNRNPA1 mutation. Neurobiol Aging. 2018 ; 61 : 255.e9-255.e16.
 
4) Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014 ; 17 : 17-23.
PubMed
5) Byrne S, Elamin M, Bede P, et al. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2012 ; 83 : 365-7.
PubMed
6) Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered. 2011 ; 71 : 281-8.
PubMed
7) Naruse H, Ishiura H, Mitsui J, et al. Burden of rare variants in causative genes for amyotrophic lateral sclerosis (ALS) accelerates age at onset of ALS. J Neurol Neurosurg Psychiatry. 2019 ; 90 : 537-42.
PubMed
8) Ryan M, Heverin M, Doherty MA, et al. Determining the incidence of familiality in ALS : A study of temporal trends in Ireland from 1994 to 2016. Neurol Genet. 2018 ; 4 : e239.
 
9) Ranganathan R, Haque S, Coley K, et al. Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia. Front Neurosci. 2020 ; 14 : 684.
PubMed
10) Benatar M, Wuu J, Fernandez C, et al. Motor neuron involvement in multisystem proteinopathy : implications for ALS. Neurology. 2013 ; 80 : 1874-80.
PubMed
P.203 掲載の参考文献
1) https://www.nanbyou.or.jp/entry/234 (最終閲覧日 : 2024年2月1日)
 
2) Hashizume A, Katsuno M, Suzuki K, et al. A functional scale for spinal and bulbar muscular atrophy : Cross-sectional and longitudinal study. Neuromuscul Disord. 2015 ; 25 : 554-62.
 
3) Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA) : a study of 223 Japanese patients. Brain. 2006 ; 129 (Pt 6) : 1446-55.
 
4) Hashizume A, Fischbeck KH, Pennuto M, et al. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA). J Neurol Neurosurg Psychiatry. 2020 ; 91 : 1085-91.
PubMed
5) 園生雅弘, 東原真奈. Fasciculation potentialとALS診断. 臨床神経. 2014 ; 54 : 1080-2.
 
6) Hashizume A, Katsuno M, Banno H, et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain. 2012 ; 135 (Pt 9) : 2838-48.
 
7) Dahlqvist JR, Oestergaard ST, Poulsen NS, et al. Refining the spinobulbar muscular atrophy phenotype by quantitative MRI and clinical assessments. Neurology. 2019 ; 92 : e548-59.
PubMed
8) Araki A, Katsuno M, Suzuki K, et al. Brugada syndrome in spinal and bulbar muscular atrophy. Neurology. 2014 ; 82 : 1813-21.
PubMed
9) Torii R, Hashizume A, Yamada S, et al. Clinical features of female carriers and prodronal patients with spinal and bulbar muscular atrophy. Neurology. 2023 ; 100 : e84-93.
 
P.207 掲載の参考文献
1) https://www.nanbyou.or.jp/entry/285 (最終閲覧日 : 2024年2月1日)
 
2) Grotto S, Cuisset JM, Marret S, et al. Type 0 spinal muscular atrophy : Further delineation of prenatal and postnatal features in 16 patients. J Neuromuscul Dis. 2016 ; 3 : 487-95.
 
3) Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014 ; 83 : 810-7.
PubMed
4) Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017 ; 82 : 883-91.
PubMed
5) Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017 ; 377 : 1723-32.
PubMed
6) Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018 ; 378 : 625-35.
PubMed
7) Day JW, Finkel RS Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE) : an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021 ; 20 : 284-93.
PubMed
8) Darras BT, Masson R, Mazurkiewicz-Beldzinska M, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021 ; 385 : 427-35.
PubMed
9) Kissel JT, Elsheikh B, King WM, et al. SMA valiant trial : a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve. 2014 ; 49 : 187-92.
 

G 感染症, 炎症性疾患

P.214 掲載の参考文献
1) 細菌性髄膜炎診療ガイドライン2014作成委員会 (作成委員会委員長 亀井聡, 他). 細菌性髄膜炎診療ガイドライン 2014. 東京 : 南江堂 ; 2014. p.1-123.
 
2) 単純ヘルペス脳炎診療ガイドライン2017作成委員会 (日本神経感染症学会・日本神経学会・日本神経治療学会, 監修. 作成委員長 亀井聡). 単純ヘルペス脳炎診療ガイドライン. 東京 : 南江堂 ; 2017. p.1-100.
 
3) 亀井聡. 成人の急性細菌性髄膜炎. 感染症症候群. 第2版. 下巻. 大阪 : 日本臨牀社 ; 2013. p.93-8.
 
4) 亀井聡. 結核菌. 神経症候群. 第2版. I, 大阪 : 日本臨牀社 ; 2013. p.812-6.
 
5) 亀井聡. 脳保護 Q&A-神経救急・集中治療におけるアプローチ. Q36. 慢性中枢神経感染症の管理. 救急・集中治療. 2011 ; 23 : 1230-5.
 
P.223 掲載の参考文献
1) 厚生労働省科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「プリオン病及び遅発性ウイルス感染症に関する調査研究班」. 進行性多巣性白質脳症 (Progressive Multifocal Leukoencephalopathy : PML) 診療ガイドライン 2023. 2023. http://prion.umin.jp/guideline/pdf/guideline_PML_temp2013.pdf
 
2) Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited : reliability, validity, and guidelines. J Clin Oncol. 1984 ; 2 : 187-93.
PubMed
3) Kurtzke JF. Rating neurologic impairment in multiple sclerosis : an expanded disability status scale (EDSS). Neurology. 1983 ; 33 : 1444-52.
PubMed
4) Mahoney FI, Barthel DW. Functional evaluation : The Barthel Index. Md State Med J. 1965 ; 14 : 61-5.
PubMed
5) Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus : clinical features and pathogenesis. Lancet Neurol. 2010 ; 9 : 425-37.
PubMed
6) Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy : a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009 ; 60 : 3761-5.
PubMed
7) Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 ; 366 : 1870-80.
PubMed
8) Marignier R, Durand-Dubief F, du Pasquier R, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis : Also consider progressive multifocal leukoencephalopathy risk. Ann Neurol. 2016 ; 80 : 791.
 
9) Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : lessons from 28 cases. Lancet Neurol. 2010 ; 9 : 438-46.
PubMed
10) Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009 ; 361 : 1081-7.
PubMed
11) Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009 ; 361 : 1075-80.
PubMed
12) Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol. 2014 ; 1 : 755-64.
PubMed
13) Major EO, Douek DC. Risk factors for rare diseases can be risky to define : PML and natalizumab. Neurology. 2013 ; 81 : 858-9.
PubMed
14) Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol. 2014 ; 27 : 260-70.
PubMed
15) Wattjes MP, Vennegoor A, Steenwijk MD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry. 2015 ; 86 : 793-8.
PubMed
16) Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria : consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013 ; 80 : 1430-8.
PubMed
P.226 掲載の参考文献
1) 厚生労働科学研究費補助金 難治性疾患等政策研究事業HAM及びHTLV-1関連希少難治性炎症性疾患の実態調査に基づく診療方針作成と診療基盤の構築をめざした政策研究班. HAM診療マニュアル 第2版. 2016.
 
2) Osame M, Igata A, Matsumoto M, et al. HTLV-1-associated myelopathy (HAM) treatment trials, Retrospective survey and clinical and laboratory findings. Hematol Rev. 1990 ; 3 : 271-84.
 
3) 厚生労働省難治性疾患製作研究事業「HAMならびにHTLV-1陽性難治性疾患に関する国際的な総意形成を踏まえた診療ガイドラインの作成」研究班 (代表 : 山野嘉久), 2017年度.
 
4) Sato T, Coler-Reilly A, Utsunomiya A, et al. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis. PLos Negl Trop Dis. 2013 ; 7 : e2479.
PubMed
5) Castro-Costa CM, Araujo AQC, Barreto MM, et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Human Retrovirus. 2006 ; 22 : 931-5.
 
6) Slater CM, Ribeiro LC, Puccioni-Sohler M. Difficulties in HAM/TSP diagnosis. Arq Neuropsiquiatr. 2012 ; 70 : 686-90.
 
7) Coler-Reilly AL, Yagishita N, Suzuki H, et al. Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet J Rare Dis. 2016 ; 11 : 69.
PubMed
8) 日本神経学会, 他監修. HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019. 東京 : 南江堂 ; 2019.
 
9) Yamakawa N, Yagishita N, Matsuo T, et al. Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet J Rare Dis. 2020 ; 3 ; 15 : 175.
 
10) Schmidt F, Oliveira AL, Arujo A. Development and validation of a neurological disability scale for patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) : The IPEC-1 Scale. Neurology. 2012 ; 78 (1 Suppl) : P03.258.
 
P.229 掲載の参考文献
1) Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV associated neurocognitive disorders. Neurology. 2017 ; 69 : 1789-99.
 
2) 山本直樹, 宮澤幸久. 診療におけるHIV-1/2感染症の診断ガイドライン 2020. 日本エイズ学会誌. 2009 ; 11 : 70-2.
 
3) Kinai E, Komatsu K, Sakamoto M, et al. Association of age and time of disease with HIV-associated neurocognitive disorders : a Japanese nationwide multicenter study. J Neurovirol. 2017 ; 23 : 864-74.
PubMed
4) Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy : differences in rates, nature, and predictors. J Neurovirol. 2011 ; 17 : 3-16.
PubMed
5) Sam N, Winston A, Letendre S, et al Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 ; 13 : 1139-51.
 
P.232 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患研究事業 プリオン病及び遅発性ウイルス感染症に関する調査研究班. 亜急性硬化症性全脳炎 (subacute sclerosing panencephalitis : SSPE) 診療ガイドライン 2020.
 
2) Jabbour JT, Garcia JH, Lemmni H, et al. Subacute sclerosing panencephalitis. A multidisciplinary study of eight case. JAMA. 1969 ; 207 : 2248-54.
 
3) Lakshmi V, Malathy Y, Rao RR. Serodiagnosis of subacute sclerosing panencephalitis by enzyme linked immunosorbent assay. Indian J Pediatr. 1993 ; 60 : 37-41.
PubMed
4) Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis : an update. Dev Med Chid Neurol. 2010 ; 52 : 901-7.
 
5) 市山高志. 亜急性硬化症性全脳炎 (SSPE). 症状・徴候と検査. 厚生労働省科学研究費補助金難治性疾患克服研究事業「プリオン病及び遅発性ウイルス感染症に関する調査研究班」, 編. プリンオン病と遅発性ウイルス感染症. 金原出版 ; 2010. p.278-82.
 
6) Bellini WJ, Helfand RF. The challenges and strategies for laboratory diagnosis of measles in an international setting. J Infect Dis. 2003 ; 187 (Suppl 1) : S283-90.
 
7) Prashanth LK, Taly AB, Ravi V, et al. Long term survival in subacute sclerosing panencephalitis : an enigma. Brain Dev. 2006 ; 28 : 447-52.
PubMed
8) Prashanth LK, Taly AB, Sinha S, et al. Subacute sclerosing panencephalitis (SSPE) : an insight into the diagnostic errors form a tertiary care university hospital. J Child Neurol. 2007 ; 22 : 683-8.
 
9) Dyken PR, Swift A, DuRant RH. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann Neurol. 1982 ; 11 : 359-64.
PubMed
P.241 掲載の参考文献
1) World Health Organization Cruetzfeldt-Jakob disease (CJD) and variant CJD (vCJD). https://www.who.int/zoonoses/diseases/Creutzfeldt.pdf
 
2) Hamaguchi T, Sanjo N, Ae R, et al. MM2-type sporadic Creutzfeldt-Jakob disease : new diagnostic criteria for MM2-cortical type. J Neurol Neurosurg Psychiatry. 2020 Aug 24 ; jnnp-2020-323231. doi : 10.1136/jnnp-2020-323231.
 
3) 2008/426/EC : Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision NO 2119/98/EC of the European Parliament and of the Council (notified under document number C (2008) 1589) [cited 2012 May 14]. Available from http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:159:0046:01:EN:HTML.
 
4) Thompson AG, Lowe J, Fox Z, et al. The Medical Research Council prion disease rating scale : a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain. 2013 ; 136 : 1116-27.
 
5) プリオン病診療ガイドライン 2020 http://prion.umin.jp/guideline/pdf/guideline_2020.pdf
 
6) Qina T, Sanjo N, Hizume M, et al. Clinical features of genetic Creutzfeldt-Jakob disease with V180I mutation in the prion protein gene. BMJ Open. 2014 ; 4 : e004698.
 
7) 山田正仁, 他. 日本におけるヒト・プリオン病のサーベイランスと疫学的実態. In : プリオン病及び遅発性ウイルス感染症に関する調査研究班, 編. プリオン病と遅発性ウイルス感染症. 東京 ; 金原出版 ; 2021. p.16-21.
 
8) Iwasaki Y. Creutzfeldt-Jakob disease. Neuropathology. 2017 ; 37 : 174-88.
PubMed
9) Mastrianni JA, Nixon R, Layzer R, et al. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med. 1999 ; 340 : 1630-8.
 
10) Hamaguchi T, Kitamoto T, Sato T, et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology. 2005 ; 64 : 643-8.
PubMed
11) Hayashi Y, Iwasaki Y, Takekoshi A, et al. An autopsy-verified case of FTLD-TDP type A with upper motor neuron-predominant motor neuron disease mimicking MM2-thalamic-type sporadic Creutzfeldt-Jakob disease. Prion. 2016 ; 10 : 492-501.
PubMed
12) Mead S, Gandhi S, Beck J, et al. A novel prion disease associated with diarrhea and autonomic neuropathy. N Engl J Med. 2013 ; 369 : 1904-14.
 
13) Matsuzono K, Ikeda Y, Liu W, et al. A novel familial prion disease causing pan-autonomic-sensory neuropathy and cognitive impairment. Eur J Neurol. 2013 ; 20 : e67-9.
 

H 脱髄性疾患, 非感染性炎症性疾患

P.251 掲載の参考文献
1) 難病情報センターホームページ. 多発性硬化症/視神経脊髄炎 (指定難病13). https://www.nanbyou.or.jp/entry/380.
 
2) Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 ; 17 : 162-73.
PubMed
3) 多発性硬化症・視神経脊髄炎スペクトラム障害診療ガイドライン作成委員会. 日本神経学会, 2023年. 日本神経学会多発性硬化症/視神経脊髄炎スペクトラム障害診療ガイドライン 2023 第1章 診断. https://www.neurology-jp.org/files/images/20230317_01_01.pdf
 
4) Kurtzke JF. Rating neurologic impairment in multiple sclerosis : an expanded disability status scale (EDSS). Neurology. 1983 ; 33 : 1444-52.
PubMed
5) Shinoda K, Matsushita T, Nakamura Y, et al. HLA-DRB1*04 : 05 allele is associated with intracortical lesions on 3-dimensional double inversion recovery images in Japanese patients with multiple sclerosis. Mult Scler. 2018 ; 24 : 710-20.
PubMed
6) Arrambide G, Tintore M, Espejo C, et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018 ; 141 : 1075-84.
PubMed
7) Yoshimura S, Isobe N, Matsushita T, et al. Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients. PLoS One. 2014 ; 9 : e95367.
PubMed
8) Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology. 2016 ; 87 : 1393-9.
PubMed
9) Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain. 2016 ; 139 : 2395-405.
PubMed
P.254 掲載の参考文献
1) Krupp1 LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions Multiple Sclerosis Journal. 2013 ; 19 : 1261-7.
 
2) 多発性硬化症・視神経脊髄炎スペクトラム障害診療ガイドライン作成委員会. 日本神経学会多発性硬化症/視神経脊髄炎スペクトラム障害診療ガイドライン 2023. 日本神経学会 : 2023. 第1章 診断. https://www.neurology-jp.org/files/images/20230317_01_01.pdf
 
3) 原寿郎, 鳥巣浩幸. 急性散在性脳脊髄炎 (ADEM). In : 楠進, 編. 免疫性神経疾患ハンドブック. 東京 : 南江堂 ; 2013. p.108-20.
 
4) Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015 ; 86 : 265-72.
 
P.259 掲載の参考文献
1) Nakashima I. Anti-myelin oligodendrocyte glycoprotein antibody in demyelinating diseases. Clin Exp Neuroimmunol. 2015 ; 6 : 59-63.
 
2) Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66 : 1485-9.
PubMed
3) Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 ; 85 : 177-89.
PubMed
4) Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO : a clinical CSF biomarker study. Neurology. 2010 ; 75 : 208-16.
PubMed
5) Kurtzke JF. Rating neurologic impairment in multiple sclerosis : an expanded disability status scale (EDSS). Neurology. 1983 ; 33 : 1444-52.
PubMed
P.265 掲載の参考文献
1) Yokoseki A, Saji E, Arakawa M, et al. Hypertrophic pachymeningitis : significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain. 2014 ; 137 : 520-36.
PubMed
2) Kupersmith MJ, Martin V, Heller G, et al. Idiopathic hypertrophic pachymeningitis. Neurology 2004 ; 62 : 686-94.
PubMed
3) Charcot JM. Lectures on the Diseases of the Nervous System. Trans by G. Sigerson. : London : The New Sydenham Society. 1877.
 
4) Naffziger HC, Stern WE. Chronic pachymeningitis ; report of a case and review of the literature. Arch Neurol Psychiatry. 1949 ; 62 : 383-411.
PubMed
5) Yonekawa T, Murai H, Utsuki S, et al. A nationwide survey of hypertrophic pachymeningitis in Japan. J Neurol Neurosurg Psychiatry. 2014 ; 85 : 732-9.
PubMed
6) 勇亜衣子, 河内泉. 【肥厚性硬膜炎-最近の話題-】肥厚性硬膜炎の歴史と概念 新たな診断基準. 脳神経内科. 2019 ; 91 : 340-51.
 
7) Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 ; 65 : 1-11.
 
8) Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007 ; 66 : 222-7.
PubMed
9) Craven A, Robson J, Ponte C, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013 ; 17 : 619-21.
PubMed
P.268 掲載の参考文献
1) 国際頭痛学会・頭痛分類委員会, (訳) 日本頭痛学会・国際頭痛分類委員会. 国際頭痛分類 第3版. 日本頭痛学会・国際頭痛分類委員会, 編. 東京 : 医学書院 ; 2018.
 
2) Tolosa E. Periarteritic lesions of the carotid siphon with the clinical features of a carotid infraclinoidal aneurysm. J Neurol Neurosurg Psychiatry. 1954 ; 17 : 300-2.
PubMed
3) Hunt WE, Meagher JN, Lefever HE, et al. Painful opthalmoplegia. Its relation to indolent inflammation of the carvernous sinus. Neurology. 1961 ; 11 : 56-62.
PubMed
4) Amrutkar C, Burton EV. Tolosa-Hunt Syndrome. (ed) : StatPearls. StatPearls Publishing. Copyright(C) 2020, StatPearls Publishing LLC., Treasure Island (FL), 2020.
 
5) Colnaghi S, Versino M, Marchioni E, et al. ICHD-II diagnostic criteria for Tolosa-Hunt syndrome in idiopathic inflammatory syndromes of the orbit and/or the cavernous sinus. Cephalalgia. 2008 ; 28 : 577-84.
PubMed
6) Zhang X, Zhang W, Liu R, et al. Factors that influence Tolosa-Hunt syndrome and the short-term response to steroid pulse treatment. J Neurol Sci. 2014 ; 341 : 13-6.
PubMed
7) Mullen E, Rutland JW, Green MW, et al. Reappraising the Tolosa-Hunt syndrome diagnostic criteria : A case series. Headache, 2020 ; 60 : 259-64.
PubMed
8) Mullen E, Green M, Hersh E, et al. Tolosa-Hunt syndrome : Appraising the ICHD-3 beta diagnostic criteria. Cephalalgia. 2018 ; 38 : 1696-700.
PubMed
9) Zhang X, Zhou Z, Steiner TJ, et al. Validation of ICHD-3 beta diagnostic criteria for 13.7 Tolosa-Hunt syndrome : Analysis of 77 cases of painful ophthalmoplegia. Cephalalgia. 2014 ; 34 : 624-32.
 
P.275 掲載の参考文献
1) Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis : From the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018 ; 75 : 1546-53.
 
2) 日本サルコイドーシス/肉芽腫性疾患学会 サルコイドーシス診療の手引き作成委員会. サルコイドーシス診療の手引き 2018. https://www.jssog.com/journal
 
3) 日本サルコイドーシス/肉芽腫性疾患学会 サルコイドーシス診療の手引き作成委員会. サルコイドーシスの診断基準と診断の手引き 2015. https://www.jssog.com/journal
 
4) Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis : systematic review and meta-analysis. BMC Neurol. 2016 ; 16 : 220.
PubMed
5) 作田学, 熊本俊秀, 飯塚高浩, 他. サルコイドーシスの神経・筋病変に関する診断基準. 脳と神経. 2006 ; 58 : 471-6.
 
6) Borden N, Linklater D. Hickam's dictum. West J Emerg Med. 2013 ; 14 : 164.
 
7) Nozaki K, Scott TF, Sohn M, et al. Isolated neurosarcoidosis : case series in 2 sarcoidosis centers. Neurologist. 2012 ; 18 : 373-7.
PubMed
8) Wegener S, Linnebank M, Martin R, et al. Clinically isolated neurosarcoidosis : a recommended diagnostic path. Eur Neurol. 2015 ; 73 : 71-7.
PubMed
9) Nozaki K, Judson MA. Neurosarcoidosis : clinical manifestations, diagnosis and treatment. Presse Med. 2012 ; 41 (6 Pt 2) : e331-48.
 
10) 辰野健太郎, 中村聖香, 朝山知子, 他. 筋症状のみを呈した慢性ミオパチー型筋サルコイドーシスの1例. 臨床神経. 2014 ; 54 : 313-6.
 
P.281 掲載の参考文献
1) Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 ; 15 : 391-404.
PubMed
2) Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014 ; 75 : 411-28.
PubMed
3) Armangue T, Moris G, Cantarin-Extremera V, et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology. 2015 ; 85 : 1736-43.
PubMed
P.290 掲載の参考文献
1) 日本ベーチェット病学会, 監修. ベーチェット病診療ガイドライン 2020. 東京 : 診断と治療社 ; 2020.
 
2) International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990 ; 335 : 1078-80.
 
3) International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD) : a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 ; 28 : 338-47.
 
4) 溝口昌子, 近兼健一朗, 朝比奈義仁, 他. Sweet病-Behcet病との関連, 診断基準など-. 皮膚臨床. 1986 ; 28 : 131-42.
 
5) Su WPD, Liu HH. Diagnostic criteria for Sweet's syndrome. Cutis. 1986 ; 25 : 167-74.
 
6) von den Driesch P. Sweet's syndrome (acute febril neutrophilic dermatosis). J Am Acad Dermatol. 1994 ; 31 : 535-56.
PubMed
7) Nofal A, Abdelmaksoud A, Amer H, et al. Sweet's syndrome : diagnostic criteria revisited. J Deutsch Dermatol Ges. 2017 ; 15 : 1081-8.
 
8) Hisanaga K, Iwasaki Y, Itoyama Y, the Neuro-Sweet Disease Study Group : Neuro-Sweet disease : Clinical manifestations and criteria for diagnosis. Neurology. 2005 ; 64 : 1756-61.
 
9) 久永欣哉. ベーチェット病およびその類縁疾患スウィート病における神経障害の病因・診断・治療. 臨床神経. 2019 ; 59 : 1-12.
 

I 代謝性疾患

P.295 掲載の参考文献
1) アミロイドーシスに関する調査研究班. 遺伝性ATTR (ATTRv) アミロイドーシスの診断基準. http://amyloidosis-research-committeejp/wp-content/uploads/2020/07/diagnostic_200702pdf.
 
2) アミロイドーシスに関する調査研究班. 全身性野生型ATTR (ATTRwt) アミロイドーシスの診断基準. http://amyloidosis-research-committeejp/wp-content/uploads/2020/07/diagnostic_200702pdf.
 
3) アミロイドーシスに関する調査研究班. 全身性ALアミロイドーシスの診断基準. http://amyloidosis-researchcommitteejp/wp-content/uploads/2020/07/diagnostic_200702pdf.
 
4) Sekijima Y, Uchiyama S, Tojo K, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome : a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011 ; 42 : 1785-91.
PubMed
5) Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome : a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016 ; 23 : 58-63.
PubMed
6) Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 ; 8 : 31.
PubMed
P.299 掲載の参考文献
1) European Association for Study of Liver. EASL clinical practice guidelines : Wilson's disease. J Hepatol. 2012 ; 56 : 671-85.
PubMed
2) ウィルソン病難病指定診断基準 https://www.nanbyou.or.jp/entry/4544
 
3) 藤井秀樹. 発症前Wilson病のセルロプラスミン及び銅代謝に関する研究, 診断基準作成の試み. Biomed Res Trace Elements. 1997 ; 8 : 75-83.
 
4) 小児慢性特定疾患診断の手引きウィルソン病 https://www.shouman.jp/disease/instructions/08_08_107/#details_related
 
5) 清水教一, 深尾敏幸, 窪田満, 他. Wilson病. In : 日本先天代謝異常学会, 編. 新生児マススクリーニング対象疾患等診療ガイドライン 2015. 東京 : 診断と治療社 ; 2015. p.202-10.
 
6) Nakamura H, Hemmi H, Shimizu N. Molecular diagnosis of Wilson disease in Japanese patients. 東邦医会誌. 2009 ; 56 : 65-70.
 
7) 児玉浩子, 青木継稔, 有馬正高, 他. Wilson病診療ガイドライン 2015. 小児の栄養消化器肝臓病診療ガイドライン・指針. 東京 : 診断と治療社 ; 2015. p.122-80.
 
P.302 掲載の参考文献
1) 日本神経学会承認無セルロプラスミン血症診断基準. https://www.neurology-jp.org/guidelinem/pdf/syounin_05.pdf
 
2) 遺伝性ジストニア (指定難病120) -難病情報センター. nanbyou.or.jp
 
3) 吉田邦広, 兼子一真. 無セルロプラスミン血症. 神経内科. 2009 ; 71 : 517-26.
 
4) Yoshida K, Fujihata K, Takeda S, et al. A mutation in the ceruloplasmin gene in associated with systemic hemosiderosis in human. Nat Genet. 1995 ; 9 : 267-72.
 
P.311 掲載の参考文献
1) Gregory A, Hayflick S. Neurodegeneration with Brain Iron Accumulation Disorders Overview. GeneReviews(R). https://www.ncbi.nlm.nih.gov/books/NBK121988/
 
2) NBIA Disorders Association. https://nbiadisorders.org/
 
3) NBIA Alliance. http://www.nbiaalliance.org/
 
4) Hogarth P. Neurodegeneration with brain iron accumulation : diagnosis and management. J Mov Disord. 2015 ; 8 : 1-13.
PubMed
5) 脳表ヘモジデリン沈着症 (指定難病122) 難病情報センター. (厚生労働省補助事業) 情報更新日 2023年6月. https://www.nanbyou.or.jp/entry/4810
 
6) Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA) : an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord. 2012 ; 27 : 42-53.
PubMed
7) Dusek P, Schneider SA. Neurodegeneration with brain iron accumulation. Curr Opin Neurol. 2012 ; 25 : 499-506.
PubMed
8) Hogarth P, Gregory A, Kruer MC, et al. New NBIA subtype : genetic, clinical, pathologic, and radiographic features of MPAN. Neurology. 2013 ; 80 : 268-75.
PubMed
9) Kim J, Liao YH, Ionita C, et al. Mitochondrial membrane protein-associated neurodegeneration mimicking juvenile amyotrophic lateral sclerosis. Pediatr Neurol. 2016 ; 64 : 83-6.
PubMed
10) Kurian MA, McNeill A, Lin JP, et al. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol. 2011 ; 53 : 394-404.
PubMed
11) 遺伝性ジストニア (指定難病120) 難病情報センター. (厚生労働省補助事業). 情報更新日 2023年11月. https://www.nanbyou.or.jp/entry/4898
 
12) 藤原広和, 百島祐貴. 神経疾患と鉄沈着. 鉄沈着の画像診断. 神経内科. 2010 ; 73 : 110-6.
 
13) 百島祐貴, 藤原広和. 鉄と神経疾患. 脳内鉄沈着をきたす疾患の画像診断. 神経内科. 2013 ; 79 : 435-8.
 
14) Sethi KD, Mehta SH, Morgan JC. Defining the eye-of-the-tiger sign. JAMA Neurol. 2015 ; 72 : 606.
PubMed
15) Dusek P, Dezortova M, Wuerfel J. Imaging of iron. Int Rev Neurobiol. 2013 ; 110 : 195-239.
PubMed
16) 高尾昌樹. 最近話題の認知症性疾患. Neurodegeneration with brain iron accumulation (NBIA). 精神科. 2016 ; 28 : 427-34.
 
17) 隅寿恵. パーキンソン病診断のコツとPitfall. パーキンソン病とパーキンソニズムをきたす疾患の鑑別のポイント. NBIAとパーキンソン病の鑑別. Frontiers in Parkinson Disease. 2015 ; 8 : 92-6.
 
18) Kruer MC, Boddaert N, Schneider SA, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol. 2012 ; 33 : 407-14.
PubMed
19) Kruer MC, Boddaert N. Neurodegeneration with brain iron accumulation : a diagnostic algorithm. Semin Pediatr Neurol. 2012 ; 19 : 67-74.
 
20) 太田恵美子, 瀧山嘉久. 日本臨牀. 別冊 新領域別症候群シリーズ 神経症候群 (第2版) II. p.297-301.
 

J 傍腫瘍性症候群

P.316 掲載の参考文献
1) Graus F, Vogrig A, Muniz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021 ; 8 : e1014.
 
2) Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 ; 75 : 1135-40.
PubMed
3) McKeon A. Purkinje cell cytoplasmic autoantibody type 1 accompaniments : The cerebellum and beyond. Arch Neurol. 2011 ; 68 : 1282-9.
PubMed
4) Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndrome : report of an EFNS task force. Eur J Neurol. 2011 ; 18 : 19-e3.
 
5) Dalmau J, Graus F. Autoimmune encephalitis and related disorders of the nervous system. Cambridge University Press ; 2022.
 
6) Simard C, Vogrig A, Jaubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e699.
 
7) Dubey D, Wilson MR, Clarkson B, et al. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis. JAMA Neurol. 2020 ; 77 : 1420-9.
PubMed
8) Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019 ; 16 : 535-48.
PubMed
P.322 掲載の参考文献
1) Graus F, Vogrig A, Muniz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021 ; 8 : e1014.
 
2) Vogrig A, Gigli GL, Segatti S, et al. Epidemiology of paraneoplastic neurological syndromes : a population-based study. J Neurol. 2019 ; 267 : 26-35.
PubMed
3) Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiaty. 1948 ; 11 : 73-8.
 
4) Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiaty. 2004 ; 75 : 1135-40.
 
5) Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes : report of an EFNS Task Force. Eur J Neurol. 2006 ; 13 : 682-90.
PubMed
6) Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndromes : report of anEFNS task force. Eur J Neurol. 2011 ; 18 : 19-27.
 
7) Sheikhbahaei S, Marcus CV, Fragomeni RS, et al. Whole body 18F-FDG PET/CT in patients with suspected paraneoplastic syndorome : a systematic review and meta-analysis of diagnostic accuracy. J Nucl Med. 2017 ; 58 : 1031-6.
 
8) Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018 ; 90 : e103-10.
PubMed
9) Hadden RDM, Nobile-Orazio E, Sommer C, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2006 ; 13 : 809-18.
PubMed
10) Devaux JJ, Miura Y, Fukami Y, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016 ; 86 : 800-7.
PubMed
11) Koike H, Watanabe H, Sobue G. The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J neurol Nerurosurg Psychiatry. 2013 ; 84 : 98-106.
 
12) Golden EP, Vernino S. Autoimmune autonomic neuropathies and ganglionopathies : epidemiology, pathophysiology, and therapeutic advances. Clinical Autonomic Research 2019 ; 29 : 277-88.
PubMed
13) Jitprapaikulsan J, Klein CJ, Pittock SJ, et al. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. J Neurol Neurosurg Psychiatry. 2020 ; 91 : 328-30.
PubMed
14) Zis P, Paladini A, Piroli A, et al. Pain as a first manifestation of paraneoplastic neuropathies : a systemic review and meta-analysis. Pain Ther. 2017 ; 6 : 143-51.
 
15) Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenstrom macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022 ; 197 : 171-87.
PubMed
16) Albadareen R, Gronseth G, Goeden M, et al. Paraneoplastic autoantibody panels : sensitivity and specificity, a retrospective cohort. Int J Neurosci. 2017 ; 127 : 531-8.
PubMed
17) Kim JT, Harris NS. Utilization review of paraneoplastic neurological syndrome antibody screening panels : experience at a Tertiary Academic Health Center. Appl Lab Med. 2019 ; 4 : 19-29.
 

K てんかんと類縁疾患

P.326 掲載の参考文献
1) Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report : a practical clinical definition of epilepsy. Epilepsia. 2014 ; 55 : 475-82.
PubMed
2) CQ1-1 てんかんとはなにか. In : 「てんかん診療ガイドライン」作成委員会, 編. てんかん診療ガイドライン 2018. 東京 : 医学書院 ; 2018. p.2-3.
 
3) 概念・定義・有病率・発生率. In : 日本てんかん学会, 編. てんかん専門医ガイドブック. 改訂第2版. 東京 : 診断と治療社 ; 2020. p.2-4.
 
4) Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy : definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005 ; 46 : 470-2.
PubMed
5) 分類 (1981年, 1989年, 2017年の比較). In : 日本てんかん学会, 編. てんかん専門医ガイドブック. 改訂第2版. 東京 : 診断と治療社 ; 2020. p.5-12.
 
6) Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy : Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 ; 58 : 522-30.
PubMed
7) Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies : Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 ; 58 : 512-21.
PubMed
8) Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age : position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 ; 63 : 1443-74.
 
9) Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy : consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 ; 51 : 1069-77.
 
10) CQ5-1 薬剤抵抗性てんかんの定義はなにか. In : 「てんかん診療ガイドライン」作成委員会, 編. てんかん診療ガイドライン 2018. 東京 : 医学書院 ; 2018. p.52-3.
 
P.332 掲載の参考文献
1) Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 ; 15 : 391-404.
PubMed
2) Sakamoto M, Matsumoto R, Togawa J, et al. Diagnostic value of algorithm for autoimmune epilepsy in a retrospective cohort. Front Neurol. 2022 ; 13 : 902157.
 
3) de Bruijn M, Bastiaansen AEM, Mojzisova H, et al. Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. Ann Neurol. 2021 ; 89 : 698-710.
PubMed
4) Geis C, Planaguma J, Carreno M, et al. Autoimmune seizures and epilepsy. J Clin Invest. 2019 ; 129 : 926-40.
 
5) Granerod J, Cousens S, Davies NWS, et al. New estimates of incidence of encephalitis in England. Emerg Infect Dis. 2013 ; 19 : 1455-62.
 
6) Dubey D. Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018 ; 83 : 166-77.
 
7) 大石真莉子, 神田隆, 渡邊修, 他. 自己免疫性脳炎の全国調査. 厚労省科研費新エビデンス班会議抄録集. 2020.
 
8) Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014 ; 82 : 1578-86.
PubMed
9) Baysal-Kirac L, Tuzun E, Erdag E, et al. Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings. J Neurol. 2016 ; 263 : 455-66.
PubMed
10) Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011 ; 69 : 892-900.
PubMed
11) von Rhein B, Wagner J, Widman G, et al. Suspected antibody negative autoimmune limbic encephalitis : outcome of immunotherapy. Acta neurologica Scandinavica. 2017 ; 135 : 134-41.
PubMed
12) Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018 ; 83 : 166-77.
 
13) Dubey D, Alqallaf A, Hays R, et al. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol. 2017 ; 74 : 397-402.
PubMed
P.338 掲載の参考文献
1) Caplan LB. Transient global amnesia. In : Frederiks JAM, editor. Handbook of clinical neurology, vol1. Clinical neuropsychology. Amsterdam : Elsevier ; 1985. p.205-18.
 
2) Hodges JR, Warlow CP. Syndromes of transient global amnesia : towards a classification. A study of 153 cases. J Neurol Neurosurg Psychiatry. 1990 ; 53 : 834-43.
 
3) Bartsch T, Deuschl G. Transient global amnesia ; Functional anatomy and clinical implication. Lancet Neurol. 2010 ; 9 : 205-14.
PubMed
4) Miller JW, Petersen RC, Metter EJ, et al. Transient global amnesia : clinical characteristics and prognosis. Nuerology. 1987 ; 37 : 733-7.
 
5) Alessandro L, Carandri IL, Suarez MF, et al. Transient global amnesia : clinical features and prognostic factors suggesting recurrence. Arq Neuropasiquiatr. 2019 ; 77 : 3-9.
 
6) Yi M, Sherzai AZ, Ani C, et al. Strong association between migraine and transient global amenesia : A national inpatinet sample analysis. J Neuropsychiatry Clin Neurosci. 2019 ; 31 : 43-8.
 
7) Kim J, Kwon Y, Yang Y, et al. Clinical experience of modified diffusion-weighted imaging protocol for lesion detection in transient global amnesia : an 8-year largescale clinical study. J Neuroimaging. 2014 ; 24 : 331-7.
 
8) Sedlaczek O, Hirsch JG, Grips E, et al. Detection of delayed focal MR changes in the lateral hippocampus in transient global amnesia. Neurology. 2004 ; 62 : 2165-70.
PubMed
9) Szabo K, Hoyer C, Caplan LR, et al. Diffusion-weighted MRI in transient global amnesia and its diagnostic implications. Neurology. 2020 ; 95 : e206-12.
PubMed
10) Bettermann K. Transient global amnesia : the continuing quest for a source. Arch Neurol. 2006 ; 63 : 1336-8.
PubMed
11) Pantoni L, Lamassa M, Inzitari D. Transient global amnesia : a review emphasizing pathogenic aspects. Acta Neurol Scand. 2000 ; 102 : 275-83.
PubMed
12) Michel P, Beaud V, Eskandari A, et al. Ischemic amnesia : causes and outcome. Stroke. 2017 : 48 : 2270-3.
PubMed
13) Forster A, Al-Zghloul M, Eisele P, et al. Hippocampal infarction : Identification of three new types. J Neuroradiol. 2018 : 45 : 1-5.
PubMed
14) Butler CR, Graham KS, Hodges JR, et al. The syndrome of transient epileptic amnesia, Ann. Neurol. 2007 : 61 : 587-98.
PubMed
15) Zeman J, Boniface SJ, Hodges JR. Transient epileptic amnesia : a description of the clinical and neuropsychological features in 10 cases and a review of the literature. J Neurol Neurosurg Psychiatry. 1998 ; 64 : 435-43.
 

L 頭痛

P.344 掲載の参考文献
1) 日本頭痛学会・国際頭痛分類委員会, 訳. 国際頭痛分類 第3版. 東京 : 医学書院 ; 2018.
 
2) Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea : a comprehensive review of the literature. J Headache Pain. 2019 ; 20 : 111.
 
3) Edvinsson L, Haanes KA. Views on migraine pathophysiology : Where does it start? Neurol Clin Neurosci, 2019 ; 8 : 120-7.
 
4) 慢性頭痛の診療ガイドライン作成委員会. II 片頭痛 2-2 片頭痛の急性期治療には, どのような方法があり, どのように使用するか. In : 日本神経学会, 日本頭痛学会, 日本神経治療学会, 監修. 頭痛の診療ガイドライン作成委員会, 編. 頭痛の診療ガイドライン 2021. 東京 : 医学書院 ; 2021. p.141-5.
 
5) 慢性頭痛の診療ガイドライン作成委員会. II-3-2 予防療法にはどのような薬剤があるか. In : 日本神経学会・日本頭痛学会, 編. 慢性頭痛の診療ガイドライン 2013. 東京 : 医学書院 ; 2013. p.148-50.
 
6) Headache Ahcoco. Classification of headache. J Am Med Assoc. 1962 ; 179 : 717-8.
 
7) Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988 ; 8 (Suppl 7) : 1-96.
 
8) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 ; 38 : 1-211.
PubMed
9) 竹島多賀夫, 間中信也, 五十嵐久佳, 他. 慢性片頭痛と薬物乱用頭痛の付録診断基準の追加について. 日本頭痛学会誌. 2007 ; 34 : 192-3.
 
10) Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999 ; 19 : 107-14.
 
11) 問診票, スクリーナーをどう利用したらよいでしょうか. In : 日本頭痛学会, 編. これで治す最先端の頭痛治療「慢性頭痛の診療ガイドライン」市民版 : 保健同人社 ; 2006 : 18-23.
 
12) Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine : third edition. A guide for investigators. Cephalalgia. 2012 ; 32 : 6-38.
PubMed
P.349 掲載の参考文献
1) 日本頭痛学会・国際頭痛分類委員会, 訳. 緊張型頭痛. 国際頭痛分類 第3版. 東京 : 医学書院 ; 2018. p.21-7.
 
2) 五十嵐久佳. 頭痛の疫学. Clinical Neuroscience. 2007 ; 25 : 516-8.
 
3) Bendtsen L, Fumal A, Schoenen J. Tension-type headache : mechanisms. Handb Clin Neurol. 2010 ; 97 : 359-66.
PubMed
4) 大熊壮尚, 北川泰久. 頭痛一次性頭痛緊張型頭痛 緊張型頭痛の発症機序. 別冊日本臨牀 神経症候群. 第2版. 大阪 : 日本臨牀社 ; 2014. p.702-6.
 
5) Jensen R, Rasmusen BK, Pedersen B, et al. Muscle tenderness and pressure pain thresholds in headache. A population study. Pain. 1993 ; 52 : 193-9.
 
6) 槻本直也, 真鍋克次郎, 四方實彦, 他. 頸椎疾患に対する評価～頭重負荷指数評価の臨床応用～. 理学療法京都. 2006 ; 35 : 110-1.
 
7) 大熊壮尚. 緊張型頭痛の科学的エビデンスとは? 日本頭痛学会会誌. 2020 ; 47 : 67-71.
 
8) Do TP, Heldarskard GF, Kolding LT, et al. Myofascial trigger pointsin migraine and tension type headache. J Headache Pain. 2018 ; 19 : 84.
 
9) Ashina S, Bendsen L, Ashina M, et al. Generalized hyperalgesia in patients with chronic tension-type headache. Cephalalgia. 2006 ; 26 : 940-8.
 
10) Bendtsen L. Sensitization : its role in primary headache. Curr Opin Investig Drugs. 2002 ; 3 : 449-53.
PubMed
P.355 掲載の参考文献
1) 日本頭痛学会・国際頭痛分類委員会, 訳. 国際頭痛分類 第3版. 東京 : 医学書院 ; 2018.
 
2) Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain. 1997 ; 120 : 193-209.
PubMed
3) インドメタシン内服剤の製造中止およびその代替品について. 日本頭痛学会ホームページより. https://www.jhsnet.net/dl/20191227_01.pdf
 
4) Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact : the HIT-6. Qual Life Res. 2003 ; 12 : 963-74.
PubMed
5) Kamm K, Straube A, Ruscheweyh R. Cluster Headache Impact Questionnaire (CHIQ) -a short measure of cluster headache related disability. J Headache Pain. 2022 ; 23 : 37.
 
6) Onofri A, Iannone LF, Granato A, et al. Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ). Neurol Sci. 2023. Online ahead of print.
 

M 睡眠疾患

P.360 掲載の参考文献
1) American Academy of Sleep Medicine. International Classification of Sleep Disorders Third Edition, Text Revision. Darien, IL : American Academy of Sleep Medicine ; 2023.
 
2) Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009 ; 5 : 263-76.
PubMed
3) Troester MM, Quan SF, Berry RB, et al. American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events version 3 : rules, terminology and technical specifications. Darien, IL : American Academy os Sleep Medicine ; 2023.
 
4) Luo YM, Tang J, Steier J, et al. Distinguishing obstructive from central sleep apnea events : Diaphragm electromyogram and esophageal pressure compared. Chest. 2009 ; 135 : 1133-41.
PubMed
5) Won CHJ. When will we ditch the AHI? J Clin Sleep Med. 2020 ; 16 : 1001-3.
 
6) Randerath W, Verbraecken J, Andreas S, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2017 ; 49 : 1600959.
PubMed
P.366 掲載の参考文献
1) American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien, IL : American Academy of Sleep Medicine ; 2014.
 
2) Yoss RE, Daly DD. Narcolepsy. Med Clin North Am. 1960 ; 44 : 953-68.
PubMed
3) 米国睡眠医学会, 著. 日本睡眠学会診断分類委員会, 訳. 睡眠障害国際分類 第3版. 東京 : ライフ・サイエンス ; 2018.
 
4) 日本睡眠学会. ナルコレプシーの診断・治療ガイドライン 2010. http://jssr.jp/data/pdf/narcolepsy.pdf (2024年1月10日参照)
 
5) 福原俊一, 竹上未紗, 鈴鴨よしみ, 他. 日本語版the Epworth Sleepiness Scale (JESS) : これまで使用されていた多くの「日本語版」との主な差異と改訂. 日本呼吸器学会雑誌. 2006 ; 44 : 896-8.
Medical*Online
6) Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors : a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998 ; 92 : 573-85.
 
7) de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins : hypothalamus-specific peptides with neuroexcitatory activity. Proc Nat Acad Sci U S A. 1998 ; 95 : 322-7.
PubMed
8) Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000 ; 355 : 39-40.
PubMed
9) 日本睡眠学会. 日本睡眠学会専門医療機関 2023. https://jssr.jp/files/list/2023nintei_kikan.pdf (2024年1月10日参照)
 
10) Ono T, Kanbayashi T, Yoshizawa K, et al. Measurement of cerebrospinal fluid orexin-A (hypocretin-1) by enzyme-linked immunosorbent assay : A comparison with radioimmunoassay. Psychiatry Clin Neurosci. 2018 ; 72 : 849-50.
PubMed
11) 筑波大学国際統合睡眠医科学研究機構Human Sleep Lab. 脳脊髄液中の睡眠・覚醒関連物質であるオレキシン等の測定研究. https://wpi-iiis.tsukuba.ac.jp/uploads/sites/2/2019/12/88d127e5d7ac2432e214a2e0826662db.pdf (2024年1月10日参照)
 
12) Kanbayashi T, Sagawa Y, Takemura F, et al. The pathophysiologic basis of secondary narcolepsy and hypersomnia. Curr Neurol Neurosci Rep. 2011 ; 11 : 235-41.
PubMed
13) Challamel MJ, Mazzola ME, Nevsimalova S, et al. Narcolepsy in children. Sleep. 1994 ; 17 (8 Suppl) : S17-20.
 
14) Ishido H, Chiba S, Takahashi H, et al. Characteristics of hypersomnia due to inflammatory demyelinating diseases of the central nervous system. BMJ Neurol Open. 2023 ; 5 : e000428.
PubMed
15) Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody : a case report and literature review. Arch Neurol. 2012 ; 69 : 1355-9.
 
16) Dauvilliers Y, Barateau L, Lopez R, et al. Narcolepsy Severity Scale : a reliable tool assessing symptom severity and consequences. Sleep. 2020 ; 43 : zsaa009.
 
17) Dauvilliers Y, Beziat S, Pesenti C, et al. Measurement of narcolepsy symptoms : The Narcolepsy Severity Scale. Neurology. 2017 ; 88 : 1358-65.
PubMed
P.376 掲載の参考文献
1) Galbiati A, Verga L, Giora E, et al. The risk of neurodegeneration in REM sleep behavior disorder : A systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. 2019 ; 43 : 37-46.
PubMed
2) Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015 ; 30 : 1600-11.
PubMed
3) 米国睡眠医学会. 日本睡眠学会診断分類委員会, 訳. 睡眠障害国際分類 第3版. 東京 : ライフサイエンス ; 2018.
 
4) 米国睡眠学会, 著. 日本睡眠学会, 訳. AASM による睡眠および随伴イベントの判定マニュアル-ルール, 用語, 技術仕様の詳細 VERSION 2.3 (日本語版). 東京 : ライフ・サイエンス ; 2017.
 
5) Stiasny-Kolster K, Mayer G, Schafer S, et al. The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord. 2007 ; 22 : 2386-93.
PubMed
6) Stiasny-Kolster K, Sixel-Doring F, Trenkwalder C, et al. Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. Sleep Med. 2015 ; 16 : 186-9.
PubMed
7) Miyamoto T, Miyamoto M, Iwanami M, et al. The REM sleep behavior disorder screening questionnaire : validation study of a Japanese version. Sleep Med. 2009 ; 10 : 1151-4.
PubMed
8) Nomura T, Inoue Y, Kagimura T, et al. Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. Sleep Med. 2011 ; 12 : 711-3.
PubMed
9) Li SX, Wing YK, Lam SP, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep Med. 2010 ; 11 : 43-8.
PubMed
10) Sasai T, Matsuura M, Wing YK, et al. Validation of the Japanese version of the REM sleep behavior disorder questionnaire (RBDQ-JP). Sleep Med. 2012 ; 13 : 913-8.
PubMed
11) Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder : a multicenter validation study. Mov Disord. 2012 ; 27 : 913-6.
PubMed
12) Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med. 2013 ; 9 : 475-80.
 
13) 笹井妙子, 井上雄一. REM睡眠行動障害のPSG記録と判定のピットフォール. 睡眠医療. 2012 ; 6 : 497-502.
Medical*Online
14) Montplaisir J, Gagnon JF, Fantini ML, et al. Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov Disord. 2010 ; 25 : 2044-51.
PubMed
15) Frauscher B, Iranzo A, Gaig C, et al. Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep. 2012 ; 35 : 835-47.
PubMed
16) Hogl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration-an update. Nat Rev Neurol. 2018 ; 14 : 40-55.
PubMed
17) Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder : isolated side effect or neurodegenerative signal? Sleep. 2013 ; 36 : 1579-85.
PubMed
18) Fernandez-Arcos A, Iranzo A, Serradell M, et al. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation : A study in 203 consecutive patients. Sleep. 2016 ; 39 : 121-32.
PubMed
19) Hogl B, Santamaria J, Iranzo A, et al. Precision medicine in rapid eye movement sleep behavior disorder. Sleep Med Clin. 2019 ; 14 : 351-62.
PubMed
20) Suzuki K, Kawasaki A, Miyamoto M, et al. Insulinoma masquerading as rapid eye movement sleep behavior disorder : Case series and literature review. Medicine (Baltimore). 2015 ; 94 : e1065.
PubMed
21) Iranzo A, Santamaria J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep. 2005 ; 28 : 203-6.
PubMed
22) Gaig C, Iranzo A, Pujol M, et al. Periodic limb movements during sleep mimicking REM sleep behavior disorder : A new form of periodic limb movement disorder. Sleep. 2017 ; 40.
PubMed
23) Wang Y, Yang Y, Wu H, et al. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016 ; 12 : 1403-9.
 
24) Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011 ; 7 : 639-44A.
PubMed
25) Trenkwalder C, Paulus W. Restless legs syndrome : pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010 ; 6 : 337-46.
PubMed
26) Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria : updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014 ; 15 : 860-73.
 
27) Hening WA, Allen RP, Washburn M, et al. The four diagnostic criteria for restless legs syndrome are unable to exclude confounding conditions ("mimics"). Sleep Med. 2009 ; 10 : 976-81.
PubMed
28) Baumann CR, Marti I, Bassetti CL. Restless legs symptoms without periodic limb movements in sleep and without response to dopaminergic agents : a restless legs-like syndrome? Eur J Neurol. 2007 ; 14 : 1369-72.
PubMed
29) Suzuki K, Suzuki H, Suzuki Y, et al. "Restless face" as a variant of restless legs syndrome. Parkinsonism Relat Disord. 2017 ; 41 : 130-1.
PubMed
30) Horvath J, Landis T, Burkhard PR. Restless arms. Lancet. 2008 ; 371 : 530.
PubMed
31) Perez-Diaz H, Iranzo A, Rye DB, et al. Restless abdomen : a phenotypic variant of restless legs syndrome. Neurology. 2011 ; 77 : 1283-6.
PubMed
32) Suzuki K, Suzuki S, Miyamoto M, et al. Involvement of legs and other body parts in patients with restless legs syndrome and its variants. J Neurol Sci. 2019 ; 407 : 116519.
PubMed
33) Inoue Y, Oka Y, Kagimura T, et al. Reliability, validity, and responsiveness of the Japanese version of International Restless Legs Syndrome Study Group rating scale for restless legs syndrome in a clinical trial setting. Psychiatry Clin Neurosci. 2013 ; 67 : 412-9.
 
34) 日本神経治療学会. 標準的神経治療 : Restless legs 症候群. 2012.
Medical*Online
35) Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary : Treatment of restless legs syndrome in adults : Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016 ; 87 : 2585-93.
 

N 脊椎・脊髄疾患

P.382 掲載の参考文献
1) 服部奨, 河合伸也. 頸椎症の臨床診断, 整形外科の立場から. In : 伊丹康人, 西尾篤人, 編. 整形外科MOOK No. 6 頸椎症の臨床. 東京 : 金原出版 ; 1979. p.13-40.
 
2) 平林洌. 日本整形外科学会頚髄症治療成績判定基準. 日整会誌. 1994 ; 68 : 490-503.
 
3) 角谷曉. 日本脊髄外科研究会 脊椎・脊髄疾患の神経症状判定基準について. 脊髄外科. 1992 ; 6 : 3-5.
 
4) 安藤哲朗. 頸椎症の診療. 臨床神経学. 2012 ; 52 : 469-79.
 
5) 日本整形外科学会診療ガイドライン委員会, 頚椎症性脊髄症診療ガイドライン策定委員会. 第3章 診断. 頚椎症性脊髄症診療ガイドライン 2020, 改訂第3版. 東京 : 南江堂 ; 2020. p.21-34.
 
6) 国分正一. 頸椎症性脊髄症における責任椎間板高位の神経学的診断. 臨整外. 1984 ; 19 : 417-24.
 
7) Seichi A, Takeshita K, Kawaguchi H, et al. Neurologic level diagnosis of cervical stenotic myelopathy. Spine. 2006 ; 31 : 1338-43.
PubMed
8) 安藤哲朗. 頸椎症性筋萎縮症の症候. 脊椎脊髄. 2009 ; 22 : 1104-9.
 
P.385 掲載の参考文献
1) 日本整形外科学会診療ガイドライン委員会, 腰椎椎間板ヘルニア診療ガイドライン策定委員会. 第3 章診断. In : 腰椎椎間板ヘルニア診療ガイドライン 2021 改訂第3版. 東京 : 南江堂 ; 2021. p.31-41.
 
2) Spangfort EV. The lumbar disc herniation. A computer-aided analysis of 2,504 operations. Acta Orthop Scand Suppl.1972 ; 142 : 1-95.
PubMed
3) Vroomen PC, de Krom MC, Wilmink JT, et al. Diagnostic value of history and physical examination in patients suspected of lumbosacral nerve root compression. J Neurol Neurosurg Psychiatry. 2002 ; 72 : 630-4.
PubMed
P.388 掲載の参考文献
1) 日本整形外科学会診療ガイドライン委員会, 脊柱靭帯骨化症診療ガイドライン策定委員会. 頸椎後縦靭帯骨化症診断基準. In : 脊柱靭帯骨化症診療ガイドライン 2019. 東京 : 南江堂 ; 2019. p.9.
 
2) 日本整形外科学会診療ガイドライン委員会, 脊柱靭帯骨化症診療ガイドライン策定委員会. 胸椎後縦靭帯骨化症診断基準. In : 脊柱靭帯骨化症診療ガイドライン 2019. 東京 : 南江堂 ; 2019. p.10.
 
3) Tsuyama N. Ossification of the posterior longitudinal ligament of the spine. Clin Orthop Relat Res. 1984 ; 184 : 71-84.
PubMed
4) 服部奨. 後縦靱帯骨化の診断と治療. 黄色靱帯骨化症を含む. 山口医会誌.1983 ; 16 : 67-88.
 
5) 柳務. 頚椎後縦靱帯骨化の臨床とレ線所見に関する研究. 脳と神経.1970 ; 22 : 909-21.
 
6) 69 後縦靭帯骨化症〔Internet〕. 東京 : 難病情報センター. 〔cited 2020 Oct. 23〕https://www.nanbyou.or.jp/wp-content/uploads/upload_files/File/069-201704-kijyun.pdf
 
7) 日本整形外科学会診療ガイドライン委員会, 脊柱靭帯骨化症診療ガイドライン策定委員会. 頸椎後縦靭帯骨化症診断・治療アルゴリズム. In : 脊柱靭帯骨化症診療ガイドライン 2019. 東京 : 南江堂 ; 2019. p.12-4.
 
P.395 掲載の参考文献
1) Konno S, Hayashino Y, Fukuhara S, et al. Development of a clinical diagnosis support tool to identify patients with lumbar spinal stenosis. Eur Spine J. 2007 ; 16 : 1951-7.
PubMed
2) 紺野愼一. 腰部脊柱管狭窄の診断サポートツールについて. 脊椎脊髄. 2008 ; 21 : 324-7.
 
3) 日本整形外科学会診療ガイドライン委員会, 腰部脊柱管狭窄症診療ガイドライン策定委員会. 第2章 診断. In : 腰部脊柱管狭窄症診療ガイドライン 2011 改訂第2版. 東京 : 南江堂 ; 2021. p.12.
 
4) Konno S, Kikuchi S, Tanaka Y, et al. A diagnostic support tool for lumbar spinal stenosis : a self-administered, self-reported history questionnaire. BMC Musculoskelet Disord. 2007 ; 8 : 102.
PubMed
5) 紺野愼一, 菊地臣一, 国分正一, 他. 腰部脊柱管狭窄の診断-自記式問診票の開発. 日整会誌. 2007 ; 81 : S254.
Medical*Online
6) Stucki G, Daltroy L, Liang MH, et al. Measurement properties of a self-administered outcome measure in lumbar spinal stenosis. Spine. 1996 ; 21 : 796-803.
PubMed
7) 原慶宏, 松平浩, 寺山星, 他. 日本語版Zurich claudication questionnaire (ZCQ) の開発-言語的妥当性を担保した翻訳版の作成. 整形外科. 2010 ; 61 : 159-65.
 
8) Arnoldi CC, Brodsky AE, Cauchoix J, et al. Lumbar spinal stenosis and nerve root entrapment syndromes. Definition and classification. Clin Orthop Relat Res. 1976 ; 115 : 4-5.
PubMed
9) Verbiest H. A radicular syndrome from developmental narrowing of the lumbar vertebral canal. J Bone Joint Surg Br. 1954 ; 36-B : 230-7.
 
10) Katz JN, Dalgas M, Stucki G, et al. Degenerative lumbar spinal stenosis. Diagnostic value of the history and physical examination. Arthritis Rheum. 1995 ; 38 : 1236-41.
PubMed
11) 大谷晃司. 神経性間欠跛行の分類. 脊椎脊髄. 2020 ; 33 : 340-1.
 
12) 鳥畠康充. 間欠跛行の分類と鑑別診断. 脊椎脊髄. 2008 ; 21 : 333-40.
 
13) Takai K, Taniguchi M. Clinical and neuroimaging findings of spinal dural arterio venous fistulas : How to avoid misdiagnosis of this disease. J Orthopaedic Sci. 2019 ; 24 : 1027-32.
 
P.400 掲載の参考文献
1) Sakushima K, Tsuboi S, Yabe I, et al. Nationwide survey on the epidemiology of syringomyelia in Japan. J Neurol Sci. 2012 ; 313 : 147-52.
PubMed
2) Sakushima K, Hida K, Yabe I, et al. Differences in surgical treatment techniques used by neurosurgeons and orthopedists for syringomyelia caused by Chiari I malformation in Japan. J Neurosurg Spine. 2013 ; 18 : 588-92.
PubMed
3) 寺江聡, 飛騨一利, 佐々木秀直. 病態を考慮した脊髄空洞症の診断. Brain and Nerve. 2011 ; 63 : 969-77.
 
4) Chang HS, Nakagawa N. Syringomyelia in neuromyelitis optica seropositive for aquaporin-4 antibody. J Neurol Neurosurg Psychiatry. 2003 ; 74 : 344-7.
 
5) Seki T, Hamauchi S, Yamazaki M, et al. Investigation of the neuropathic pain caused by syringomyelia associated with Chiari I malformation. Asian Spine J. 2019 ; 13 : 648-53.
PubMed
P.405 掲載の参考文献
1) Pallis CA, Louis S, Morgan RL, et al. Radiation myelopathy. Brain. 1961 ; 84 : 460-79.
PubMed
2) 日本放射線腫瘍学会, 編. 放射線治療計画ガイドライン 2020年版. p.48-58.
 
3) Rampling R, Symonds P. Radiation myelopathy. Curr Opin Neurol. 1998 ; 11 : 627-32.
PubMed
4) Mul VE, de Jong JM, Murrer LH, et al. Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer. Strahlenther Onkol. 2012 ; 188 : 71-6.
PubMed
5) McCunniff A, Liang MJ. Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1989 ; 16 : 675-8.
PubMed
6) Marcus RB Jr, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1990 ; 19 : 3-8.
 
7) Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010 ; 76 : S42-S49.
PubMed
8) 嶋崎晴雄, 中野今治. 放射線照射による脊髄障害と神経叢障害. Brain and Nerve. 2008 ; 60 : 115-21.
 
9) Kerkovsky M, Zitterbartova J, Pour L, et al. Diffusion tensor imaging in radiation-induced myelopathy. J Neuroimaging. 2015 ; 25 : 836-40.
PubMed
10) 塚越設貴, 池田将樹, 田野しのぶ, 他. 5年の寛解期の後に再発した遅発性放射線脊髄症の1例. 臨神経. 2010 ; 50 : 393-8.
 
11) 塚越設貴, 池田将樹, 池田佳生. 放射線脊髄症 (ATRMとCPRM). 別冊日本臨牀. 新領域別症候群シリーズ No.30. p.869-72.
 
12) 塚越設貴, 池田佳生. 放射線脊髄症. Clinical Neuroscience. 2019 ; 37 : 1316-8.
 
13) Ropper AH, Samuels MA. Radiation injury of the spinal cord. In : Sydor AM, Davik KJ, editors. Adams and Victors's principles of neurology. New York : McGraw-Hill ; 2009. p.1188-90.
 
14) Okada S, Okeda R. Pathology of radiation myelopathy. Neuropathology. 2001 ; 21 : 247-65.
PubMed
15) Glantz MJ, Burger PC, Friedman AH, et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology. 1994 ; 44 : 2020-7.
PubMed
16) Chamberlain MC, Eaton KD, Fink J, et al. Radiation-induced myelopathy : treatment with bevacizumab. Arch Neurol. 2011 ; 68 : 1608-9.
PubMed
17) Psimaras D, Tafani C, Ducray F, et al. Bevacizumab in late-onset radiation-induced myelopathy. Neurology. 2016 ; 86 : 454-7.
PubMed
18) Canedo G, Solis I, Gonzalez-San Segundo C, et al. Treatment of radiation-induced myelopathy with bevacizumab. Clin Transl Oncol. 2020 ; 22 : 957-60.
PubMed

O 末梢神経疾患

P.416 掲載の参考文献
1) Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol. 1978 ; 3 : 565-6.
PubMed
2) Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990 ; 27 : S21-4.
PubMed
3) Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barre syndrome and fisher syndrome : case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011 ; 29 : 599-612.
PubMed
4) Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978 ; 2 : 750-3.
PubMed
5) 日本神経学会, 監修. 「ギラン・バレー, フィッシャー症候群診療ガイドライン」作成委員会, ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 東京 : 南江堂 ; 2013.
 
6) Tan CY, Omaira Razali SN, Goh KJ, et al. Diagnosis of Guillain-Barre syndrome and validation of the Brighton criteria in Malaysia. J Peripher Nerv Syst. 2020 ; 25 : 256-64.
 
7) van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barre syndrome. Eur J Neurol. 2023 ; 30 : 3646-74. (J Peripher Nerv Syst. 2023 ; 28 : 535-63.)
 
8) Wakerley BR, Uncini A, Yuki N, et al. Guillain-Barre and Miller Fisher syndromes-new diagnostic classification. Nat Rev Neurol. 2014 ; 10 : 537-44.
 
9) Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barre syndrome in ten steps. Nat Rev Neurol. 2019 ; 15 : 671-83.
PubMed
10) Koga M, Kusunoki S, Kaida K, et al. Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis : epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry. 2012 ; 83 : 1210-5.
PubMed
11) Plasma Exchange/Sandoglobulin Guillain-Barre syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997 ; 349 : 225-30.
 
12) Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barre syndrome : a systematic review. Brain. 2007 ; 130 : 2245-57.
PubMed
13) Van Schaik IN, Leger JM, Nobile-Orazio E, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Joint Task Force of the EFNS and the PNS. J Peripher Nerv Syst. 2010 ; 15 : 295-301.
PubMed
14) Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001 ; 50 : 195-201.
PubMed
15) Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988 ; 24 : 73-8.
PubMed
16) Yeh WZ, Dyck PJ, van den Berg LH, et al. Multifocal motor neuropathy : controversies and priorities. J Neurol Neurosurg Psychiatry. 2020 ; 91 : 140-8.
PubMed
17) 日本神経学会, 監修. 「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会. 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013. 東京 : 南江堂 ; 2013.
 
18) Galban-Horcajo F, Vlam L, Delmont E, et al. The diagnostic utility of determining anti-GM1 : GalC complex antibodies in multifocal motor neuropathy : a validation study. J Neuromuscul Dis. 2015 ; 2 : 157-65.
PubMed
P.424 掲載の参考文献
1) Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975 ; 50 : 621-37.
PubMed
2) Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol. 2010 ; 17 : 356-63.
PubMed
3) Ogata H, Matsuse D, Yamasaki R, et al. A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 29-36.
PubMed
4) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. 1991 ; 41 : 617-8.
 
5) Rajabally YA, Nicolas G, Pieret F, et al. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy : a multicentre European study. J Neurol Neurosurg Psychiatry. 2009 ; 80 : 1364-8.
PubMed
6) Ogata H, Yamasaki R, Hiwatashi A, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015 ; 2 : 960-71.
PubMed
7) Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP : diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019 ; 90 : 125-32.
PubMed
8) Kawamura N, Yamasaki R, Yonekawa T, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology. 2013 ; 81 : 714-22.
PubMed
9) Ogata H, Zhang X, Inamizu S, et al. Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol. 2020 ; 7 : 2297-309.
PubMed
10) Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second Revision. J Peripher Nerv Syst. 2021 Jun 4. doi : 10.1111/jns.12455. Epub ahead of print. PMID : 34085743.
 
P.430 掲載の参考文献
1) CMT診療マニュアル編集委員会 編. シャルコー・マリー・トゥース病診療マニュアル 改訂2版. 京都 : 金芳堂 ; 2015. p.127.
 
2) Shy ME, Blake J, Hahn AF, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005 ; 64 : 1209-14.
PubMed
3) Murphy SM, Herrmann DN, Reilly MM, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011 ; 16 : 191-8.
PubMed
4) Wang W, Guedj M, Attarian S, et al. A Rasch analysis of the Charcot-Marie-Tooth neuropathy score (CMTNS) in a cohort of Charcot-Marie-Tooth type 1A patients. PLoS One. 2017 ; 12 : e0169878.
 
5) Mori L, Prada V, Schenone A, et al. Outcome measeres in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects. Eur J Phys Rehabili Med. 2019 ; 55 ; 47-55.
 
6) Bjelica B, Peric S, Stojanovic V, et al. Neuropathic pain in patients with Charcot-Marie-Tooth type 1A. Neurol Sci. 2020 ; 41 : 625-30.
 
P.435 掲載の参考文献
1) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害の簡易診断基準の改訂について. 末梢神経. 2006 ; 17 : 101.
 
2) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害の病期分類. 末梢神経. 2006 ; 17 : 102-3.
 
3) Goto Y, Hotta N, Shigeta Y, et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother. 1995 ; 49 : 269-77.
PubMed
4) Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies : update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 ; 33 : 2285-93.
PubMed
5) Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006 ; 29 : 1294-9.
PubMed
6) Suichi T, Misawa S, Sato Y, et al. Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry. 2019 ; 90 : 133-7.
PubMed
7) Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome : definitions and long-term outcome. Blood. 2003 ; 101 : 2496-506.
PubMed
8) Kuwabara S, Dispenzieri A, Arimura K, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. The Cochrane Database Syst Rev. 2012 : CD006828.
PubMed
9) Misawa S, Sato Y, Katayama K, et al. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response : retrospective cohort study. BMJ Open. 2015 ; 5 : e009157.
PubMed
10) Nasu S, Misawa S, Sekiguchi Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2012 ; 83 : 476-9.
PubMed
11) Suichi T, Misawa S, Sekiguchi Y, et al. Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease. J Neurol Sci. 2020 ; 413 : 116771.
PubMed
P.439 掲載の参考文献
1) Kuhlenbaumer G, Stogbauer F, Timmerman V, et al. Diagnostic guidelines for hereditary neuralgic amyotrophy or heredofamilial neuritis with brachial plexus predilection. On behalf of the European CMT Consortium. Neuromuscul Disord. 2000 ; 10 : 515-7.
 
2) Peripheral Nerve 末梢神経. 2017 ; 28 : 387-8.
 
3) Kuhlenbaumer G, Hannibal MC, Nelis E, et al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat Genet. 2005 ; 37 : 1044-6.
PubMed
4) van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain. 2006 ; 129 : 438-50.
PubMed
5) Ferrante MA, Wilbourn AJ. Lesion distribution among 281 patients with sporadic neuralgic amyotrophy. Muscle Nerve. 2017 ; 55 : 858-61.
PubMed
6) Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017 ; 13 : 302-16.
PubMed
7) ArAnyi Z, Csillik A, DeVay K, et al. Ultrasonography in neuralgic amyotrophy : Sensitivity, spectrum of findings, and clinical correlations. Muscle Nerve. 2017 ; 56 : 1054-62.
PubMed

P 自律神経疾患

P.446 掲載の参考文献
1) Sletten DM, Suarez GA, Low PA, et al. COMPASS 31 : a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012 ; 87 : 1196-201.
PubMed
2) Vernino S, Adamski J, Kryzer T, et al. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology. 1998 ; 50 : 1806-13.
PubMed
3) Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000 ; 343 : 847-55.
PubMed
4) Pavy-Le Traon A, Amarenco G, Duerr S, et al. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011 ; 26 : 1985-92.
PubMed
5) Kim Y, Seok JM, Park J, et al. The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism. PLoS One. 2017 ; 12 : e0180744.
 
6) Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018 ; 379 : 11-21.
PubMed
7) Iodice V, Kimpinski K, Vernino S, et al. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology. 2009 ; 72 : 2002-8.
PubMed
8) Nakane S, Mukaino A, Higuchi O, et al. A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy. J Autoimmun. 2020 ; 108 : 102403.
PubMed
9) Sandroni P, Low PA. Other autonomic neuropathies associated with ganglionic antibody. Auton Neurosci. 2009 ; 146 : 13-7.
PubMed
10) Watari M, Nakane S, Mukaino A, et al. Autoimmune postural orthostatic tachycardia syndrome. Ann Clin Transl Neurol. 2018 ; 5 : 486-92.
PubMed
11) Mukaino A, Minami H, Isomoto H, et al. Anti-ganglionic AChR antibodies in Japanese patients with motility disorders. J Gastroenterol. 2018 ; 53 : 1227-40.
PubMed
12) Golden EP, Bryarly MA, Vernino S. Seronegative autoimmune autonomic neuropathy : a distinct clinical entity. Clin Auton Res. 2018 ; 28 : 115-23.
PubMed
13) Bouxin M, Schvartz B, Mestrallet S, et al. Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy : Case-report and literature review. J Neuroimmunol. 2019 ; 326 : 28-32.
PubMed
14) Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc. 1993 ; 68 : 748-52.
PubMed

Q 神経筋接合部疾患

P.453 掲載の参考文献
1) 日本神経学会, 監修. 重症筋無力症/ランバート・イートン筋無力症候群診療ガイドライン 2022. 東京 : 南江堂 ; 2022.
 
2) Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis : Executive summary. Neurology. 2016 ; 87 : 419-25.
PubMed
3) Narayanaswami P, Sanders DB, Wolfe GI, et al. International Consensus Guidance for Management of Myasthenia Gravis : 2020 Update. Neurology. 2021 ; 96 : 114-22.
 
4) Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999 ; 52 : 1487-9.
PubMed
5) Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis : recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America (MGFA). Neurology. 2000 ; 55 : 16-23.
 
6) Burns TM, Conaway M, Sanders DB. The MG Composite : A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010 ; 74 : 1434-40.
PubMed
7) Gilhus NE, Nacu A, Andersen JB, et al. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015 ; 22 : 17-23.
PubMed
8) Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome : electrodiagnostic findings and response to treatment. Neurology. 2000 ; 54 : 2176-8.
PubMed
9) Sanders DB, Cao L, Massey JM, et al. Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis? Clin Neurophysiol. 2014 ; 125 : 1274-7.
PubMed
10) Oh SJ, Kurokawa K, Claussen GC, et al. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005 ; 32 : 515-20.
PubMed
P.457 掲載の参考文献
1) Ohno K, Ohkawara B, Shen XM, et al. Clinical and pathologic features of congenital myasthenic syndromes caused by 35 genes-a comprehensive review. Int J Mol Sci. 2023 ; 24 : 3730.
PubMed
2) Rodriguez Cruz PM, Belaya K, Basiri K, et al. Clinical features of the myasthenic syndrome arising from mutations in GMPPB. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 802-9.
PubMed
3) Ohno K. Is the serum creatine kinase level elevated in congenital myasthenic syndrome? J Neurol Neurosurg Psychiatry. 2016 ; 87 : 801.
PubMed
4) Byring RF, Pihko H, Tsujino A, et al. Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. Neuromuscul Disord. 2002 ; 12 : 548-53.
PubMed
5) Mannikko R, Wong L, Tester DJ, et al. Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome : a case-control study. Lancet. 2018 ; 391 : 1483-92.
PubMed
6) Parr JR, Andrew MJ, Finnis M, et al. How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child. 2014 ; 99 : 539-42.
PubMed
7) Nicole S, Chaouch A, Torbergsen T, et al. Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain. 2014 ; 137 : 2429-43.
PubMed
8) Banwell BL, Russel J, Fukudome T, et al. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol. 1999 ; 58 : 832-46.
PubMed
9) Maselli RA, Ng JJ, Anderson JA, et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet. 2009 ; 46 : 203-8.
PubMed
10) Lalani SR, Zhang J, Schaaf CP, et al. Mutations in PURA cause profound neonatal hypotonia, seizures, and encephalopathy in 5q31.3 microdeletion syndrome. Am J Hum Genet. 2014 ; 95 : 579-83.
PubMed
11) Hunt D, Leventer RJ, Simons C, et al. Whole exome sequencing in family trios reveals de novo mutations in PURA as a cause of severe neurodevelopmental delay and learning disability. J Med Genet. 2014 ; 51 : 806-13.
PubMed
12) Van Haute L, O'Connor E, Diaz-Maldonado H, et al. TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease. Nat Commun. 2023 ; 14 : 1009.
PubMed
13) Escobar V, Bixler D, Gleiser S, et al. Multiple pterygium syndrome. Am J Dis Child. 1978 ; 132 : 609-11.
PubMed
14) Shen XM, Nakata T, Mizuno S, et al. Impaired gating of gamma- and epsilon-AChR respectively causes Escobar syndrome and fast-channel myasthenia. Ann Clin Transl Neurol. 2023 ; 10 : 732-43.
PubMed
15) Huang K, Li J, Ito M, et al. Gene expression profile at the motor endplate of the neuromuscular junction of fast-twitch muscle. Front Mol Neurosci. 2020 ; 13 : 154.
 
16) Takeda JI, Nanatsue K, Yamagishi R, et al. InMeRF : prediction of pathogenicity of missense variants by individual modeling for each amino acid substitution. NAR Genom Bioinform. 2020 ; 2 : lqaa038.
PubMed
17) Takeda JI, Fukami S, Tamura A, et al. IntSplice2 : prediction of the splicing effects of Intronic single-nucleotide variants using lightGBM modeling. Front Genet. 2021 ; 12 : 701076.
PubMed
18) Joudaki A, Takeda J-i, Masuda A, et al. FexSplice : a lightGBM-based model for predicting the splicing effect of a single nucleotide variant affecting the first nucleotide G of an exon. Genes. 2023 ; 14 : 1765.
PubMed

R 筋ジストロフィー

P.463 掲載の参考文献
1) 筋ジストロフィーの標準的医療普及のための調査研究班, 編. ジストロフィノパチー診断手順. 2020.8.25 公開 https://doctors.mdcst.jp/diagnosis/dystrophinopathy/
 
2) 筋ジストロフィーの標準的医療普及のための調査研究班編. 筋ジストロフィーの病型診断を進めるための手引き (肢帯型・先天性・筋強直性ジストロフィーを念頭に) 第1.1版. 2022.7.7 公開. https://doctors.mdcst.jp/3) 久留聡, 編. 筋疾患の画像診断アトラス. 東京 : 医学書院 ; 2023.
 
4) 松家豊, 野島元雄. プロジェクト III-B 臨床病態の解析「運動機能」. 厚生省神経筋疾患研究委託費筋ジストロフィー症の疫学, 臨床および治療に関する研究-昭和57年度. 1983. p.44-9
 
5) Vignos PJ, Wagner MB, Karlinchak B, et al. Evaluation of a program for long-term treatment of Duchenne muscular dystrophy : experience at the University Hospitals of Cleveland. J Bone Joint Surg Am. 1996 ; 78 : 1844-52.
 
6) 麻所奈緒子, 望月仁志, 酒井和江, 他. Duchenne型筋ジストロフィーの手指の機能分類に関する研究-第2報-. 厚生労働省精神・神経疾患研究委委託費筋ジストロフィーの療養と自立支援のシステム構築に関する研究. 平成17～19年度総括研究報告書, 2008. p.263-8.
 
7) Brooke MH, Fenichel GM, Griggs RC, et al. CIDD Group. Duchenne muscular dystrophy : patterns of clinical progression and effects of supportive therapy. Neurology. 1989 ; 39 : 475-81.
 
8) Steffensen B, Hyde S, Lyager S, et al. Validity of the EK scale : a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int. 2001 : 6 ; 119-34.
PubMed
9) 久留聡, 鈴木重明, 尾方克久, 他. 診断未確定慢性ミオパチーにおける壊死性ミオパチー関連抗体スクリーニング. 臨床神経学. 2017 ; 57 : 562-6.
 
10) Matsui M, Inoue K, Matsumura T, et al. Screening for late-onset Pompe disease in undiagnosed myopathies. Neurology and Clinical Neuroscience. 2017 ; 5 : 60-4.
 
11) Straub V, Murphy A, Udd B, et al. 229th ENMC international workshop : Limb girdle muscular dystrophies-Nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul Disord. 2018 ; 28 : 702-10.
PubMed
12) 上田敏. Duchenne型筋ジストロフィー症児の障害段階の再検討. 厚生省神経筋疾患研究委託費研究報告書 筋ジストロフィーの疫学, 臨床および治療に関する研究-昭和57年度. 1983. p.93-6.
 
13) 松家豊, 新田英二, 白井陽一郎. 筋ジストロフィー症の上肢機能障害の評価に関する研究. 厚生省神経筋疾患研究委託費研究報告書 筋ジストロフィー症の疫学, 臨床および治療に関する研究-昭和57年度. 1983. p.116-21.
 
14) McDonald C, Henricson E, Abresch R, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy : longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013 ; 48 : 343-56.
PubMed
15) McDonald C, Henricson E, Abresch R, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy : reliability, concurrent validity, and minimal clinically important differences from a multicentre study. Muscle Nerve. 2013 ; 48 : 357-68.
PubMed
16) Mercuri E, Coratti G, Messina S, et al. Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy. PLoS One. 2016 ; 11 : e0160195.
PubMed
P.467 掲載の参考文献
1) Tawil R, Kissel JT, Heatwole C, et al. Evidence-based guideline summary : Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy : Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2015 ; 85 : 357-64.
 
2) 林由起子, 後藤加奈子, 西野一三. 顔面肩甲上腕型筋ジストロフィー. 臨床神経. 2012 ; 52 : 1154-7.
 
3) Darras BT. Facioscapulohumeral muscular dystrophy. In : Nordli DR, Shefner JM, editors. UpToDate. Waltham. UpToDate Inc ; 2024. (Accessed on January 22, 2024)
 
4) 大矢寧. 顔面肩甲上腕型筋ジストロフィー. In : 青木正志, 編. 筋疾患診療ハンドブック. 東京 : 中外医学社 ; 2013. p.152-9.
 
5) Padberg GW, Lunt PW, Koch M, et al. Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 1991 ; 1 : 231-4.
PubMed
6) Lemmers RJLF, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science. 2010 ; 329 : 1650-3.
PubMed
7) Banerji CRS, Zammit PS. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy : roles of DUX4 and PAX7. EMBO Mol Med. 2021 ; 13 : e13695.
PubMed
8) Eva Sidlauskaite E, Le Gall L, Mariot V, et al. DUX4 expression in FSHD muscles : focus on its mRNA regulation. J Pers Med. 2020 ; 10 : 73.
 
9) 国立精神・神経医療研究センター神経研究所疾病研究 第一部. 顔面肩甲上腕型筋ジストロフィーの遺伝学的診断. https://www.ncnp.go.jp/nin/guide/r1/FSHD.html (2024年2月2日閲覧)
 
10) 埜中征哉, 西野一三. 顔面肩甲上腕型筋ジストロフィー. In : 臨床のための筋病理. 第5版. 東京 : 日本医事新報社 ; 2021. p.99-102.
 
11) 日本神経学会, 日本小児神経学会, 国立精神・神経医療研究センター, 監修. 「デュシェンヌ型筋ジストロフィー診療ガイドライン」作成委員会, 編. DMDの運動機能評価はどのように行うか. In : デュシェンヌ型筋ジストロフィー診療ガイドライン 2014. 東京 : 南江堂 ; 2014. p.32-6.
 
P.470 掲載の参考文献
1) 林由起子. Emery-Dreifuss型筋ジストロフィー. In : 青木正志, 編. 筋疾患診療ハンドブック. 東京 : 中外医学社 ; 2013. p.160-4.
 
2) Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary : Diagnosis and treatment of limbgirdle and distal dystrophies. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2014 ; 83 : 1453-63.
 
3) Darras BT. Emery-Dreifuss muscular dystrophy. In : Nordli DR, Shefner JM, editors. UpToDate. Waltham. UpToDate Inc ; 2022. (Accessed on January 22, 2024.)
 
4) 埜中征哉, 西野一三. Emery-Dreifuss型筋ジストロフィー. In : 臨床のための筋病理. 第5版. 東京 : 日本医事新報社 ; 2021. p.102-6.
 
5) 日本神経学会, 日本小児神経学会, 国立精神・神経医療研究センター, 監修. 「デュシェンヌ型筋ジストロフィー診療ガイドライン」作成委員会, 編. DMDの運動機能評価はどのように行うか. In : デュシェンヌ型筋ジストロフィー診療ガイドライン 2014. 東京 : 南江堂 ; 2014. p.32-6.
 
P.475 掲載の参考文献
1) Mathieu J, De Braekeleer M, Prevost C, et al. Myotonic dystrophy : clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation. Neurology. 1992 ; 42 : 203-8.
 
2) Theadom A, Rodrigues M, Roxburgh R, et al. Prevalence of muscular dystrophies : a systematic literature review. Neuroepidemiology. 2014 ; 43 : 259-68.
PubMed
3) Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy : expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992 ; 21 ; 68 : 799-808.
 
4) Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet. 2006 ; 15 : 2087-97.
PubMed
5) Yoshimura N, Otake M, Igarashi K, et al. Topography of Alzheimer's neurofibrillary change distribution in myotonic dystrophy. Clin Neuropathol. 1990 ; 9 : 234-9.
PubMed
6) Sergeant N, Sablonniere B, Schraen-Maschke S, et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet. 2001 ; 10 : 2143-55.
PubMed
7) Leroy O, Wang J, Maurage CA, et al. Exon 6 brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1. Biochim Biophys Acta. 2006 ; 1762 : 460-7.
PubMed
8) Caillet-Boudin ML, Fernandez-Gomez FJ, Tran H, et al. Brain pathology in myotonic dystrophy : when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci. 2014 ; 6 : 57.
 
9) Jiang H, Mankodi A, Swanson MS, et al. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet. 2004 ; 13 : 3079-88.
PubMed
10) Renoux AJ, Todd PK. Neurodegeneration the RNA way. Prog Neurobiol. 2012 ; 97 : 173-89.
PubMed
11) 高橋正紀. 筋強直性ジストロフィー-RNA病としての病態から. 臨床神経学. 2012 ; 52 ; 1393-6.
 
12) Hermans MC, Faber CG, Vanhoutte EK, et al. Peripheral neuropathy in myotonic dystrophy type 1. Journal of the peripheral nervous system. JPNS. 2011 ; 16 : 24-9.
PubMed
13) Peric S., Stojanovic VR, Nikolic A, et al. Peripheral neuropathy in patients with myotonic dystrophy type 1. Neurol Res. 2013 ; 35 : 331-5.
PubMed
14) 尾方克, 久河野智, 小宮正, 他. 呼吸機能と夜間酸素飽和度の対比からみたDuchenne型および筋強直性ジストロフィーにおける呼吸不全の相違. 臨床神経. 1996 ; 36 : 850-3.
 
15) 野崎園子. 筋ジストロフィーの摂食・嚥下障害-Duchenne型筋ジストロフィーと筋強直性ジストロフィー. IRYO. 2007 ; 61 : 381-8.
Medical*Online
16) Nakamori M, Takahashi MP. Myotonic dystrophy. Translational research in muscular dystrophy. (Springer Japan ; 2016). p.39-61.
 
17) 井村裕夫, 高橋桂一, 姜進, 他. Myotonic Dystrophyにおける内分泌異常. 厚生省神経疾患研究委託費筋ジストロフィー症の疫学, 病態および治療開発に関する研究. 昭和60年度研究報告書. 1986. p.205-7.
 
18) Takada H, Kon S, Oyama Y. Therapeutic effect of metformin against insulin resistance in myotonic dystrophy type 1. Neuromuscul Disord. 2011 ; 21 : 717.
 
19) 高田博仁, 小山慶信, 今清覚, 他. 筋強直性ジストロフィーtype 1における耐糖能障害. 臨床神経学. 2012 ; 52 : 1259-60.
 
20) Fujino H, Shingaki H, Suwazono S, et. al. Cognitive impairment and quality of life in patients with myotonic dystrophy type 1. Muscle Nerve. 2018 ; 57 : 742-8.
 
21) Fujino H, Suwazono S, Takado S. Clinical features of the central nervous system. In : Takahashi MP, Matsumura T, editors. Myotonic dystrophy disease mechanism, current management and therapeutic development. Springer Singapore ; 2018. p.77-94.
 
22) 諏訪園秀吾, 上田幸彦, 前堂志乃. 筋強直性ジストロフィーの標準的医療. 筋強直性ジストロフィーの認知機能について. 神経内科. 2016 ; 85 : 270-4.
 
23) Mathieu J, Allard P, Potvin L, et al. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology. 1999 ; 52 : 1658-62.
 
24) West SD, Lochmuller H, Hughes J, et al. Sleepiness and sleep-related breathing disorders in myotonic dystrophy and responses to treatment : a prospective cohort study. J Neuromuscul Dis. 2016 ; 3 : 529-37.
PubMed
25) Boussaid G, Lofaso F, Santos DB, et al. Factors influencing compliance with non-invasive ventilation at long-term in patients with myotonic dystrophy type 1 : A prospective cohort. Neuromuscul Disord. 2016 ; 26 : 666-74.
PubMed
26) 高橋正紀. 筋強直性ジストロフィーの臨床および病態機序. 脳神経内科. 2019 ; 91 : 436-42.
 
27) 高橋正紀, 山本理紗, 久保田智哉, 他. 本邦における筋強直性ジストロフィーの患者実態調査-患者対象全国調査-. 臨床神経学. 2020 ; 60 : 130-6.
 
28) 日本神経学会, 監修. 筋強直性ジストロフィー診療ガイドライン編集委員会, 編集. 筋強直性ジストロフィー診療ガイドライン 2020. 東京 ; 南江堂 ; 2020.
 
29) Kurauchi G, Endo M, Odaira K, et al. Caregiver burden and related factors among caregivers of patients with myotonic dystrophy type 1. J Neuromuscul Dis. 2019 ; 6 : 527-36.
PubMed
30) Nakagawa M, Yamada H, Higuchi I, et al. A case of paternally inherited congenital myotonic dystrophy. J Med Genet. 1994 ; 31 : 397-400.
PubMed
31) 石垣景子, 武藤順子, 大澤真木子. 小児期発症の筋強直性ジストロフィーの臨床とケア. 臨床神経. 2012 ; 52 : 1264-6.
 
32) Vydra DG, Rayi A. Myotonic Dystrophy. 2020 Jul 4. In : StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing ; 2020.
 
33) 大澤真木子, 猪子香代, 武藤順子. 小児期筋強直性ジストロフィーの臨床. 脳と発達. 2009 ; 41 : 163.
Medical*Online
34) The International Myotonic Dystrophy Consortium (IDMC). New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). Neurology. 2000 ; 54 : 1218-21.
PubMed
35) 川井班による筋ジストロフィー患者の機能評価測定尺度集 http://www.pmdrinsho.jp/PMDscale.pdf (2020年10月10日参照)
 
36) Urata Y, Nakamura M, Shiokawa N, et al. Sleep disorders in four patients with myotonic dystrophy type 1. Front Neurol. 2020 ; 11 : 12.
PubMed
37) Dauvilliers YA, Laberge L. Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. Sleep Med Rev. 2012 ; 16 : 539-45.
PubMed
38) Itoh H, Hisamatsu T, Tamura T, et al. Cardiac conduction disorders as markers of cardiac events in myotonic dystrophy type 1. J Am Heart Assoc. 2020 ; 9 : e015709.
PubMed
39) Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019 ; 140 : e382-482.
 
40) Nieuwenhuis S, Okkersen K, Widomska J, et al. Insulin signaling as a key moderator in myotonic dystrophy type 1. Front Neurol. 2019 ; 10 : 1229.
PubMed
41) Mori I, Fujino H, Matsumura T, et al. The myotonic dystrophy health index : Japanese adaption and validity testing. Muscle Nerve. 2019 ; 59 : 577-82.
PubMed
42) Fujino H, Saito T, Takahashi MP, et al. Validation of the individualized neuromuscular quality of life in Japanese patients with myotonic dystrophy. Muscle Nerve. 2018 ; 58 : 56-63.
 
43) Okkersen K, Jimenez-Moreno C, Wenninger S, et al. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1 : a multicentre, single-blind, randomised trial. Lancet Neurol. 2018 ; 17 : 671-80.
PubMed
44) Cumming SA, Jimenez-Moreno C, Okkersen K, et al. Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort. Neurology. 2019 ; 93 : e995-e1009. Erratum in : Neurology. 2020 ; 94 : 459.
 
45) Biere J, Okkersen K, van Alfen N, et al. Characterization of EEG-based functional brain networks in myotonic dystrophy type 1. Clin Neurophysiol. 2020 ; 131 : 1886-95.
PubMed
46) Heskamp L, Okkersen K, van Nimwegen M, et al. Quantitative muscle MRI depicts increased muscle mass after a behavioral change in myotonic dystrophy type 1. Radiology. 2020 ; 297 : 132-42.
PubMed
47) Suwazono S, Arao H, Ueda Y, et al. Event-related potentials using the auditory novel paradigm in patients with myotonic dystrophy. J Neurol. 2021 ; 268 : 2900-7.
PubMed

S 筋炎・ミオパチー

P.481 掲載の参考文献
1) Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004 ; 14 : 337-45.
PubMed
2) Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop : Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018 ; 28 : 87-99.
PubMed
3) Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies : what progress has been made in the past 35 years? Chest. 2010 ; 138 : 1464-74.
PubMed
4) IMACS FORM 07A : Myositis Disease Activity Assessment Tool (MDAAT) -2005, Version 2 2015. https://www.niehs.nih.gov/research/resources/assets/docs/myositis_disease_activity_assessment_tool_2009_pdf_format_508.pdf
 
5) Sultan SM, Allen E, Oddis CV, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum. 2008 ; 58 : 3593-9.
PubMed
6) Alexanderson H, Broman L, Tollback A, et al. Functional index-2 : Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2006 ; 55 : 114-22.
PubMed
7) Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 ; 292 : 344-7.
PubMed
8) Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I : Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984 ; 16 : 193-208.
 
9) Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003 ; 362 : 971-82.
PubMed
10) De Bleecker JL, De Paepe B, Aronica E, et al. 205th ENMC International Workshop : Pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015 ; 25 : 268-72.
PubMed
11) Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 2018 ; 75 : 1528-37.
PubMed
12) Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 1038-44.
PubMed
13) Anquetil C, Boyer O, Wesner N, et al. Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmunity Rev. 2019 ; 18 : 223-30.
 
14) Liang W-C, Uruha A, Suzuki S, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford, England). 2017 ; 56 : 287-93.
 
15) 久留聡, 鈴木重明, 尾方克久, 他. 診断未確定慢性ミオパチーにおける壊死性ミオパチー関連抗体スクリーニング. 臨床神経学. 2017 ; 50 : 562-6.
 
16) Noguchi E, Uruha A, Suzuki S, et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 2017 ; 74 : 992-9.
PubMed
17) Liang W, Uruha A, Suzuki S, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies. Neuromuscul Disord. 2016 ; 26 : S143-S4.
 
18) Oyama M, Ohnuki Y, Uruha A, et al. Association between HLA alleles and autoantibodies in dermatomyositis defined by sarcoplasmic expression of myxovirus resistance protein A. J Rheumatol. 2023 : jrheum.2022-132.
 
19) Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with antiaminoacyl-tRNA synthetase antibodies : heterogeneity within the syndrome. PLoS One. 2013 ; 8 : e60442.
 
20) Inoue M, Tanboon J, Hirakawa S, et al. Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies. JAMA Neurology. 2020 ; 77 : 872-7.
PubMed
21) Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 ; 76 : 1955-64.
PubMed
22) Casal-Dominguez M, Pinal-Fernandez I, Pak K, et al. Performance of the 2017 EULAR/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis & Rheumatology 2021.
 
23) Tanboon J, Nishino I. Classification of idiopathic inflammatory myopathies : pathology perspectives. Curr Opin Neurol. 2019 ; 32 : 704-14.
PubMed
24) Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis : Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ). Arthritis Care Res. 2011 ; 63 : S118-57.
PubMed
P.488 掲載の参考文献
1) Lundberg IE, Tjarnlund A, Bottai M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups : a methodology report. Ann Rheum Dis. 2017 ; 76 : 1955-64/Arthritis Rheumatol. 2017 ; 69 : 2271-82.
 
2) Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001 ; 40 : 1262-73.
PubMed
3) Sultan SM, Allen E, Oddis CV, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum. 2008 ; 58 : 3593-9.
PubMed
4) Alexanderson H, Broman L, Tollback A, et al. Functional index-2 : Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2006 ; 55 : 114-22.
PubMed
5) Yassaee M, Fiorentino D, Okawa J, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol. 2010 ; 162 : 669-73.
PubMed
6) Jinnin M, Ohta A, Ishihara S, et al. First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Ann Rheum Dis. 2020 ; 79 : 387-92.
PubMed
7) Concha JSS, Pena S, Gaffney RG, et al. Developing classification criteria for skin-predominant dermatomyositis : the Delphi process. Br J Dermatol. 2020 ; 182 : 410-7.
PubMed
8) Inoue M, Tanboon J, Hirakawa S, et al. Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies. JAMA Neurol. 2020 ; 77 : 872-7.
PubMed
9) Huber AM, Dugan EM, Lachenbruch PA, et al. The Cutaneous Assessment Tool : development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford). 2007 ; 46 : 1606-11.
PubMed
10) Carroll CL, Lang W, Snively B, et al. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol. 2008 ; 158 : 345-50.
PubMed
11) Klein RQ, Bangert CA, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol. 2008 ; 159 : 887-94.
PubMed
P.495 掲載の参考文献
1) Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 ; 292 : 344-7.
PubMed
2) Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 ; 292 : 403-7.
PubMed
3) Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995 ; 38 : 705-13.
PubMed
4) Rose MR and Group EIW. 188th ENMC International Workshop : Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013 ; 23 : 1044-55.
 
5) Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014 ; 83 : 426-33.
PubMed
6) Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009 ; 40 : 19-31.
 
7) Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008 ; 79 : 1186-9.
PubMed
8) Olive M, Janue A, Moreno D, et al. TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol. 2009 ; 68 : 262-73.
PubMed
9) Kusters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol. 2009 ; 117 : 209-11.
PubMed
10) D'Agostino C, Nogalska A, Engel WK, et al. In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol. 2011 ; 37 : 315-20.
 
11) Hiniker A, Daniels BH, Lee HS, et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun. 2013 ; 1 : 29.
PubMed
12) Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One. 2011 ; 6 : e20266.
PubMed
13) Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013 ; 73 : 408-18.
 
14) Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013 ; 73 : 397-407.
PubMed
15) Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016 ; 75 : 696-701.
PubMed
16) Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5'-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken). 2016 ; 68 : 66-71.
PubMed
17) Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 373-8.
PubMed
18) Lilleker JB, Rietveld A, Pye SR, et al. Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis. 2017 ; 76 : 862-8.
 
19) Tawara N, Yamashita S, Zhang X, et al. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol. 2017 ; 81 : 512-25.
PubMed
20) Matsuura E, Umehara F, Nose H, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection : eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol. 2008 ; 67 : 41-9.
PubMed
21) Inamori Y, Higuchi I, Inoue T, et al. Inclusion body myositis coexisting with hypertrophic cardiomyopathy : an autopsy study. Neuromuscul Disord. 2012 ; 22 : 747-54.
PubMed
22) Yamasaki Y, Mukaino A, Yamashita S, et al. Macroglossia in rapidly progressive inclusion body myositis. Neuropathology. 2023 ; 43 : 252-6.
PubMed
23) Shibata S, Izumi R, Hara T, et al. Five-year history of dysphagia as a sole initial symptom in inclusion body myositis. J Neurol Sci. 2017 ; 381 : 325-7.
PubMed
24) Jackson CE, Barohn RJ, Gronseth G, et al. Inclusion body myositis functional rating scale : a reliable and valid measure of disease severity. Muscle Nerve. 2008 ; 37 : 473-6.
 
25) Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis : implications for clinical trials. Neuromuscul Disord. 2013 ; 23 : 404-12.
PubMed
26) DeMuro C, Lewis S, Lowes L, et al. Development of the sporadic inclusion body myositis physical functioning assessment. Muscle Nerve. 2016 ; 54 : 653-7.
PubMed
27) Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT) : a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019 ; 18 : 834-44.
PubMed
28) Benveniste O, Hogrel J-Y, Belin L, et al. Sirolimus for treatment of patients with inclusion body myositis : a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol. 2021 ; 3 : e40-8.
PubMed
P.504 掲載の参考文献
1) Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018 ; 57 : 522-30.
PubMed
2) Fournier E, Viala K, Gervais H, et al. Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol. 2006 ; 60 : 356-65.
PubMed
3) Tan SV, Matthews E, Barber M, et al. Refined exercise testing can aid DNA based diagnosis in muscle channelopathies. Ann Neurol. 2011 ; 69 : 328-40.
PubMed
4) 筋チャネル病 遺伝性周期性四肢麻痺 非ジストロフィー性ミオトニー症候群 診療の手引き. https://www.neurology-jp.org/guidelinem/pdf/syounin_03.pdf
 
5) Vivekanandam V, Mannkko R, Matthews E, et al. Improving genetic diagnostics of skeletal muscle channelopathies. Expert Rev Mol Diagn. 2020 ; 20 : 725-36.
 
6) Perez-Riera AR, Barbosa-Barros R, Samesina N, et al. Andersen-Tawil Syndrome : A comprehensive review. Cardiol Rev. 2020 (in press)
 
7) GNEミオパチー診療の手引き. https://www.neurology-jp.org/guidelinem/pdf/gne_tebiki.pdf
 
8) 眼咽頭遠位型ミオパチー診療の手引き. https://www.neurology-jp.org/guidelinem/pdf/om_tebiki.pdf
 
9) Ishiura H, Shibata S, Yoshimura J, et al. Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistalmyopathy and an overlapping disease. Nat Genet. 2019 ; 51 : 1222-32.
 
10) Ogasawara M, Iida A, Kumutpongpanich T, et al. CGG expansion in NOTCH2NLC is associated with oculopharyngodistal myopathy with neurological manifestations. Acta Neuropathol Commun. 2020 ; 8 : 204
PubMed
P.506 掲載の参考文献
1) Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain. 2012 ; 135 : 1767-77.
PubMed
2) Uenaka T, Kowa H, Ohtsuka Y, et al. Less limb muscle involvement in myositis patients with anti-mitochondrial antibodies. Eur Neurol. 2017 ; 78 : 290-5.
PubMed
3) Mauhin W, Mariampillai K, Allenbach Y, et al. Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. Joint Bone Spine. 2018 ; 85 : 375-6.
 
4) Albayda J, Khan A, Casciola-Rosen L, et al. Inflammatory myopathy associated with anti-mitochondrial antibodies : A distinct phenotype with cardiac involvement. Semin Arthritis Rheum. 2018 ; 47 : 552-6.
PubMed
5) Hou Y, Liu M, Luo YB, et al. Idiopathic inflammatory myopathies with anti-mitochondrial antibodies : Clinical features and treatment outcomes in a Chinese cohort. Neuromuscul Disord. 2019 ; 29 : 5-13.
 
6) Zhang L, Yang H, Lei J, et al. Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. Semin Arthritis Rheum 2021 ; 51 : 741-8.
 
7) Sabbagh SE, Pinal-Fernandez I, Casal-Dominguez M, et al. Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. Clin Rheumatol. 2021 ; 40 : 4095-100.
PubMed
8) Gaur PS, R N, Anuja AK, et al. Anti-mitochondrial antibodies in Indian patients with idiopathic inflammatory myopathies. Int J Rheum Dis. 2022 ; 25 : 659-68.
PubMed
9) Nagai A, Nagai T, Yaguchi H, et al. Clinical features of anti-mitochondrial M2 antibody-positive myositis : case series of 17 patients. J Neurol Sci. 2022 ; 442 : 120391.
PubMed
10) Nomiya H, Hamano T, Takaku N, et al. Magnetic resonance imaging findings of the lower limb muscles in anti-mitochondrial M2 antibody-positive myositis. Neuromuscul Disord. 2023 ; 33 : 74-80.
PubMed
P.514 掲載の参考文献
1) 小牧宏文. 先天性ミオパチーの診断基準. 厚生労働科学研究費補助金「希少難治性筋疾患に関する調査研究」班・平成26年度総括・分担研究報告書. 2015. p.34-7.
 
2) Jungbluth H, Voermans NC. Congenital myopathies : not only a paediatric topic. Curr Opin Neurol. 2016 ; 29 : 642-50.
 
3) Mah JK, Joseph JT. An Overview of congenital myopathies. Continuum (Minneap Minn). 2016 ; 22 : 1932-53.
PubMed
4) 埜中征哉. 先天性ミオパチー. 臨床のための筋病理. 第4版増補. 東京 : 日本医事新報社 ; 2014. p.110-31.
 
5) Naddaf E, Milone M, Kansagra A, et al. Sporadic late-onset nemaline myopathy : Clinical spectrum, survival, and treatment outcomes. Neurology. 2019 ; 93 : e298-305.
PubMed
6) 衞藤義勝. ポンペ病. ライソゾーム病・ペルオキシソーム病診断の手引き. 東京 : 診断と治療社 ; 2015. p.45-6.
 
7) Bellotti AS, Andreoli L, Ronchi D, et al. Molecular approaches for the treatment of Pompe disease. Mol Neurobiol. 2020 ; 57 : 1259-80.
PubMed
8) Kohler L, Puertollano R, Raben N. Pompe disease : From basic science to therapy. Neurotherapeutics. 2018 ; 15 : 928-42.
PubMed
9) Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha] -glucosidase : major clinical benefits in infantile-onset Pompe disease. Neurology. 2007 ; 68 : 99-109.
PubMed
10) 杉江和馬. Pompe病における治療の進歩. In : 園生雅弘, 他編. 脳神経疾患最新の治療 2021-2023. 東京 : 南江堂 ; 2021. p.35-8.
 
11) 杉江和馬. 自己貪食空胞性ミオパチーの診断基準確立と治療法開発に関する研究. 厚生労働科学研究費補助金「自己貪食空胞性ミオパチーの診断基準確立と治療法開発に関する研究」班・平成22～23年度総合研究報告書. 2012. p.1-14.
 
12) Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000 ; 406 : 906-10.
PubMed
13) Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology. 2002 ; 58 : 1773-8.
PubMed
14) Sugie K, Komaki H, Eura N, et al. A Nationwide survey on Danon disease in Japan. Int J Mol Sci. 2018 ; 19 : E3507.
 
15) 杉江和馬. 自己貪食空胞性ミオパチーとオートファジー. Annual Review神経 2017. 東京 : 中外医学社 ; 2017. p.39-46.
 
16) Sugie K, Noguchi S, Kozuka Y, et al. Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies. J Neuropathol Exp Neurol. 2005 ; 64 : 513-22.
PubMed
17) Ramachandran N, Munteanu I, Wang P, et al. VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy. Acta Neuropathol. 2013 ; 125 : 439-57.
PubMed
18) Sugie K, Yoshizawa H, Onoue K, et al. Early onset of cardiomyopathy and intellectual disability in a girl with Danon disease associated with a de novo novel mutation of the LAMP2 gene. Neuropathology. 2016 ; 36 : 561-5.
 

T ミトコンドリア病

P.526 掲載の参考文献
1) 須藤章. MELASの診断の進め方は? In : ミトコンドリア病診療マニュアル編集委員会, 村山 圭, 小坂仁, 三牧正和, 作成. ミトコンドリア病診療マニュアル 2023. 東京 ; 診断と治療社 : 2023. p.145-8.
 
2) Schaefer AM, Phoenix C, Elson JL, et al. Mitochondrial disease in adults : a scale to monitor progression and treatment. Neurology. 2006 ; 66 : 1932-4.
PubMed
3) Phoenix C, Schaefer AM, Elson JL, et al. A scale to monitor progression and treatment of mitochondrial disease in children. Neuromuscul Disord. 2006 ; 16 : 814-20.
PubMed
P.534 掲載の参考文献
1) 2014年度-2016年度「難治性疾患実用化研究事業 難病克服プロジェクト」 (厚生労働省・AMED) 「ミトコンドリア病診療の質を高める, レジストリシステムの構築, 診断基準・診療ガイドラインの策定および診断システムの整備を行う臨床研究 (研究代表者 : 村山圭) 」実施報告書.
 
2) 小川えりか. Leigh 脳症の診断の進め方は? (臨床検査). In : 日本ミトコンドリア学会, 編. ミトコンドリア病診療マニュアル 2023. 東京 : 診断と治療社 ; 2023. p.59-63.
 
3) 難病情報センター. ミトコンドリア病 (指定難病21) https://www.nanbyou.or.jp/entry/335
 
4) Baertling F, Rodenburg RJ, Schaper J, et al. A guide to diagnosis and treatment of Leigh syndrome. J Neurol Neurosurg Psychiatry. 2014 ; 85 : 257-65.
PubMed
5) Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome : clinical features and biochemical and DNA abnormalities. Ann Neurol. 1996 ; 39 : 343.
PubMed
6) Ruhoy IS, Saneto RP. The genetics of Leigh syndrome and its implications for clinical practice and risk management. Appl Clin Genet. 2014 7 : 221-3.
PubMed
7) 平松有, 他. CPEO/KSSの症状は? In : 日本ミトコンドリア学会, 編. ミトコンドリア病診療マニュアル 2023. 東京 : 診断と治療社 ; 2023. p.179-81.
 

U 白質ジストロフィー

P.539 掲載の参考文献
1) 難病情報センターホームページ. 副腎白質ジストロフィー (指定難病20). https://www.nanbyou.or.jp/entry/329
 
2) Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy : a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994 ; 15 : 1761-6.539
 
4) Huffnagel IC, van Ballegoij WJC, van Geel BM, et al. Progression of myelopathy in males with adrenoleukodystrophy : towards clinical trial readiness. Brain. 2019 : 142 ; 334-43.
PubMed
5) Matsukawa T, Yamamoto T, Honda A, et al. Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. Brain Commun. 2020 ; 2 : fcz048.
PubMed
6) Moser AB, Seeger E, Raymond GV. Newborn screening for X-linked adrenoleukodystrophy : post, present, and future. J Neunatal Screen. 2022 ; 8 : 16.
 
7) 日本先天代謝異常学会, 編. 副腎白質ジストロフィー (ALD) 診療ガイドライン 2019. 東京 : 診断と治療社 ; 2019
 
P.544 掲載の参考文献
1) クラッベ病臨床調査個人票. https://www.mhlw.go.jp/content/10900000/001135206.pdf
 
2) 異染性白質ジストロフィー臨床調査個人票. https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000157627.pdf
 
3) The Online Metabolic and Molecular Bases of Inherited Disease ; Krabbe disease (Globoid Cell Leukodystrophy), doi : 10.1036/ommbid.178
 
4) Hossain MA, Otomo T, Saito S, et al. Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form. Gene. 2014 ; 534 : 144-54.
 
5) The Online Metabolic and Molecular Bases of Inherited Disease ; Metachromatic Leukodystrophy. doi : 10.1036/ommbid.179
 
P.550 掲載の参考文献
1) 難治性疾患政策研究事業. 神経核内封入体病 (Neuronal Intranuclear Inclusion disease : NIID) の疾患概念確立および診断基準作成に関する研究班 2019 [Available from : https://www.nanbyou.or.jp/entry/6031 https://www.nanbyou.or.jp/wp-content/uploads/upload_files/R1_kenkyumeibo_201904_04.pdf.
 
2) Lindenberg R, Rubinstein LJ, Herman MM, et al. A light and electron microscopy study of an unusual widespread nuclear inclusion body disease. A possible residuum of an old herpesvirus infection. Acta Neuropathol (Berl). 1968 ; 10 : 54-73.
PubMed
3) Takahashi-Fujigasaki J. Neuronal intranuclear hyaline inclusion disease. Neuropathology. 2003 ; 23 : 351-9.
PubMed
4) Sone J, Tanaka F, Koike H, et al. Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Neurology. 2011 ; 76 : 1372-6.
PubMed
5) Sone J, Mori K, Inagaki T, et al. Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain. 2016 ; 139 (Pt 12) : 3170-86.
 
6) Sone J, Kitagawa N, Sugawara E, et al. Neuronal intranuclear inclusion disease cases with leukoencephalopathy diagnosed via skin biopsy. J Neurol Neurosurg Psychiatry. 2014 ; 85 : 354-6.
PubMed
7) Sone J, Mitsuhashi S, Fujita A, et al. Long-read sequencing identifies GGC repeat expansion in human-specific NOTCH2NLC associated with neuronal intranuclear inclusion disease. Biorxiv. 2019 ; doi : https://doi.org/10.1101/515635.
 
8) Sone J, Mitsuhashi S, Fujita A, et al. Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nat Genet. 2019 ; 51 : 1215-21.
PubMed
9) Ishiura H, Shibata S, Yoshimura J, et al. Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. Nat Genet. 2019 ; 51 : 1222-32.
 
10) Nakano Y, Takahashi-Fujigasaki J, Sengoku R, et al. PML nuclear bodies are altered in adult-onset neuronal intranuclear hyaline inclusion disease. J Neuropathol Exp Neurol. 2017 ; 76 : 585-94.
PubMed
11) Gelpi E, Botta-Orfila T, Bodi L, et al. Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome : a morphological and molecular dilemma. Brain. 2017 ; 140 : e51.
 
12) Padilha IG, Nunes RH, Scortegagna FA, et al. MR Imaging features of adult-onset neuronal intranuclear inclusion disease may be indistinguishable from fragile x-associated tremor/ataxia syndrome. AJNR Am J Neuroradiol. 2018 ; 39 : E100-E1.
PubMed
13) Toko M, Ohshita T, Kurashige T, et al. FXTAS is difficult to differentiate from neuronal intranuclear inclusion disease through skin biopsy : a case report. BMC Neurol. 2021 ; 21 : 396.
PubMed
14) 難治性疾患政策研究事業. 難治性筋疾患班. 希少難治性筋疾患に関する調査研究. 2016.
 
15) Schotland DL, Rowland LP. Muscular dystrophy. Features of ocular myopathy, distal myopathy, and myotonic Dystrophy. Arch Neurol. 1964 ; 10 : 433-45.
PubMed
16) Jaspar HH, Bastiaensen LA, ter Laak HJ, et al. Oculopharyngodistal myopathy with early onset and neurogenic features. Clin Neurol Neurosurg. 1977 ; 80 : 272-82.
PubMed
17) Satoyoshi E, Kinoshita M. Oculopharyngodistal myopathy. Arch Neurol. 1977 ; 34 : 89-92.
PubMed
18) van der Sluijs BM, ter Laak HJ, Scheffer H, et al. Autosomal recessive oculopharyngodistal myopathy : a distinct phenotypical, histological, and genetic entity. J Neurol Neurosurg Psychiatry. 2004 ; 75 : 1499-501.
PubMed
19) Deng J, Yu J, Li P, et al. Expansion of GGC repeat in GIPC1 Is associated with oculopharyngodistal myopathy. Am J Hum Genet. 2020 ; 106 : 793-804.
 
20) Saito R, Shimizu H, Miura T, et al. Oculopharyngodistal myopathy with coexisting histology of systemic neuronal intranuclear inclusion disease : Clinicopathologic features of an autopsied patient harboring CGG repeat expansions in LRP12. Acta Neuropathol Commun. 2020 ; 8 : 75.
PubMed
21) Ogasawara M, Iida A, Kumutpongpanich T, et al. CGG expansion in NOTCH2NLC is associated with oculopharyngodistal myopathy with neurological manifestations. Acta Neuropathol Commun. 2020 ; 8 : 204.
PubMed
22) Durmus H, Laval SH, Deymeer F, et al. Oculopharyngodistal myopathy is a distinct entity : clinical and genetic features of 47 patients. Neurology. 2011 ; 76 : 227-35.
PubMed
P.555 掲載の参考文献
1) Konno T, Yoshida K, Mizuta I, et al. Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation. Eur J Neurol. 2018 ; 25 : 142-7.
PubMed
2) Ikeuchi T, Mezaki N, Miura T. Cognitive dysfunction and symptoms of movement disorders in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Parkinsonism Relat Disord. 2018 ; 46 (Suppl 1) : S39-41.
 
3) Konno T, Kasanuki K, Ikeuchi T, et al. CSF1R-related leukoencephalopathy : a major player in primary microgliopathies. Neurology. 2018 ; 91 : 1092-104.
 
4) Wider C, Van Gerpen JA, DeArmond S, et al. Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD) : a single entity? Neurology. 2009 ; 72 : 1953-9.
 
5) Konno T, Yoshida K, Mizuno T, et al. Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Eur J Neurol. 2017 ; 24 : 37-45.
PubMed
6) Konno T, Broderick DF, Mezaki N, et al. Diagnostic value of brain calcifications in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. AJNR Am J Neuroradiol. 2017 ; 38 : 77-83.
PubMed
7) Tamhankar PM, Zhu B, Tamhankar VP, et al. Biallelic hypomorphic mutations in CSF1R associated with fatal childhood neurodegeneration. Neuropediatrics. 2020 ; 51 : 302-6.
 
8) Oosterhof N, Chang IJ, Karimiani EG, et al. Homozygous mutations in CSF1R cause a pediatric-onset leukoencephalopathy and can result in congenital absence of microglia. Am J Hum Genet. 2019 ; 104 : 936-47.
 
9) Sundal C, Carmona S, Yhr M, et al. An AARS variant as the likely cause of Swedish type hereditary diffuse leukoencephalopathy with spheroids. Acta Neuropathol Commun. 2019 ; 7 : 188.
PubMed
10) Lynch DS, Zhang WJ, Lakshmanan R, et al. Analysis of mutations in AARS2 in a series of CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. JAMA Neurol. 2016 ; 73 : 1433-9.
 
11) Mochel F, Delorme C, Czernecki V, et al. Haematopoietic stem cell transplantation in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. J Neurol Neurosurg Psychiatry. 2019 ; 90 : 1375-6.
PubMed
12) Kurtzke JF. Rating neurologic impairment in multiple sclerosis : An expanded disability status scale (EDSS). Neurology. 1983 ; 33 : 1444-52.
PubMed

V 血管炎症候群

P.567 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013 ; 65 : 1-11.
 
2) Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007 ; 66 : 222-7.
PubMed
3) Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017 ; 13 : 302-16.
PubMed
4) Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy : executive summary. J Peripher Nerv Syst. 2010 ; 15 : 176-84.
 
5) Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022 ; 81 : 1654-60.
PubMed
6) Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022 ; 81 : 1647-53.
PubMed
7) Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994 ; 87 : 671-8.
PubMed
8) Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009 ; 68 : 1827-32.
PubMed
9) 日本循環器学会. 厚生労働省. 厚生労働省難治性疾患政策研究事業難治性血管炎に関する調査研究班. 血管炎症候群の診療ガイドライン (2017年改訂版). 2018.
 
10) Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody : possible arbovirus aetiology? Br Med J (Clin Res Ed). 1982 ; 285 : 606.
PubMed
11) Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 ; 33 : 1122-8.
PubMed
12) Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008 ; 372 : 234-45.
PubMed
13) Hata A, Noda M, Moriwaki R, et al. Angiographic findings of Takayasu arteritis : new classification. Int J Cardiol. 1996 ; 54 Suppl : S155-63.
 
14) Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis : a cohort study. Rheumatology (Oxford). 2015 ; 54 : 463-70.
PubMed
15) 下島恭弘. 全身性血管炎と末梢神経障害. 脳神経内科. 2019 ; 91 : 287-94.
 
16) Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 ; 77 : 636-43.
PubMed
17) Chung JW, Kim HC, Choi YH, et al. Patterns of aortic involvement in Takayasu arteritis and its clinical implications : evaluation with spiral computed tomography angiography. J Vasc Surg. 2007 ; 45 : 906-14.
PubMed
18) Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET : a systematic literature review and meta-analysis. Medicine (Baltimore). 2015 ; 94 : e622.
PubMed
19) Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012 ; 41 : 866-71.
 
20) Ponte C, Martins-Martinho J, Luqmani RA. Diagnosis of giant cell arteritis. Rheumatology (Oxford). 2020 ; 59 : iii5-iii16.
PubMed
21) Zheng Y, Zhang Y, Cai M, et al. central nervous system involvement in ANCA-associated vasculitis : what neurologists need to know. Front Neurol. 2018 ; 9 : 1166.
 
22) Shimojima Y, Kishida D, Hineno A, et al. Hypertrophic pachymeningitis is a characteristic manifestation of granulomatosis with polyangiitis : A retrospective study of anti-neutrophil cytoplasmic antibody-associated vasculitis. Int J Rheum Dis. 2017 ; 20 : 489-96.
PubMed
23) 下島恭弘, 池田修一. チャーグ・ストラウス症候群. In : 辻省次, 吉良潤一, 編. 免疫性神経疾患-病態と治療のすべて. 東京 : 中山書店 ; 2016. p.331-7.
 
24) De Luna G, Terrier B, Kaminsky P, et al. Central nervous system involvement of granulomatosis with polyangiitis : clinical-radiological presentation distinguishes different outcomes. Rheumatology (Oxford). 2015 ; 54 : 424-32.
PubMed
25) Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, et al. Diagnosis and classification of polyarteritis nodosa. J Autoimmun. 2014 ; 48-9 : 84-9.
 
26) Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022 ; 81 : 321-6.
PubMed
27) Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022 ; 81 : 315-20.
PubMed
28) Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022 ; 81 : 309-14.
PubMed
29) Morgan AJ, Schwartz RA. Cutaneous polyarteritis nodosa : a comprehensive review. Int J Dermatol. 2010 ; 49 : 750-6.
PubMed
30) Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV) : A retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol. 2017 ; 27 : 87-94.
PubMed
31) Sada KE, Harigai M, Amano K, et al. Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Mod Rheumatol. 2016 ; 26 : 730-7.
 
32) Imboden JB. Involvement of the peripheral nervous system in polyarteritis nodosa and antineutrophil cytoplasmic antibodies-associated vasculitis. Rheum Dis Clin North Am. 2017 ; 43 : 633-9.
PubMed
P.572 掲載の参考文献
1) Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy : executive summary. J Peripher Nerv Syst. 2010 ; 15 : 176-84.
 
2) Morozumi S, Koike H, Tomita M, et al. Spatial distribution of nerve fiber pathology and vasculitis in microscopic polyangiitis-associated neuropathy. J Neuropathol Exp Neurol. 2011 ; 70 : 340-8.
PubMed
3) Koike H, Sobue G. Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Nephrol. 2013 ; 17 : 683.
PubMed
4) Koike H, Akiyama K, Saito T, et al. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) : a multicenter, double-blind trial. J Neurol. 2015 ; 262 : 752-9.
 
5) Takahashi M, Koike H, Ikeda S, et al. Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurol Neuroimmunol Neuroinflamm. 2017 ; 4 : e407.
PubMed
6) Nishi R, Koike H, Ohyama K, et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology. 2020 ; 94 : e1726-37.
PubMed
7) Sugiura M, Koike H, Iijima M, et al. Clinicopathologic features of nonsystemic vasculitic neuropathy and microscopic polyangiitis-associated neuropathy : a comparative study. J Neurol Sci. 2006 ; 241 : 31-7.
PubMed
8) Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain. 1987 ; 110 : 843-53.
PubMed
9) Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 ; 65 : 1-11.
 
P.576 掲載の参考文献
1) Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine. 1988 ; 67 : 20-39.
PubMed
2) Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol. 2009 ; 66 : 704-9.
PubMed
3) Beuker C, Strunk D, Rawal R, et al. Primary Angiitis of the CNS : a systematic review and meta-analysis. Neurol Neuroimmunol Neuroinflamm. 2021 ; 8 : e1093.
PubMed
4) Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 ; 65 : 1-11.
 
5) McVerry F, McCluskey G, McCarron P, et al. Diagnostic test results in primary CNS vasculitis : A systematic review of published cases. Neurol Clin Pract. 2017 ; 7 : 256-65.
PubMed
6) Kon T, Funamizu Y, Suzuki C, et al. A long interval from a spinal cord lesion to a subsequent brain lesion in primary central nervous system vasculitis. Intern Med. 2019 ; 58 : 1485-9.
 
7) Agarwal A, Sharma J, Srivastava MVP, et al. Primary CNS vasculitis (PCNSV) : a cohort study. Sci Rep. 2022 ; 12 : 13494.
PubMed
8) Salvarani C, Brown RD, Hunder GG. Adult primary central nervous system vasculitis. Lancet. 2012 ; 380 : 767-77.
PubMed
9) Salvarani C, Brown RD, Jr., Christianson T, et al. An update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis : description of 163 patients. Medicine. 2015 ; 94 : e738.
 
10) Haji-Ali RA, Calabrese LH. Primary angiitis of the central nervous system. Autoimmun Rev. 2013 ; 12 : 463-6.
 
11) Hecker C, Welponer T, Herold M, et al. Update on treatment strategies for vasculitis affecting the central nervous system. Drug Discov Today. 2022 ; 27 : 1142-55.
PubMed
12) Patzig M, Forbrig R, Kupper C, et al. Diagnosis and follow-up evaluation of central nervous system vasculitis : an evaluation of vessel-wall MRI findings. J Neurol. 2022 ; 269 : 982-96.
PubMed

W 内科疾患に伴う神経障害, その他

P.583 掲載の参考文献
1) Marchioli R, Finazzi G, Barbui T, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005 ; 23 : 2224-32.
 
2) Chim CS, Kwong YL, Liang R, et al. Long-term outcome of 231 patients with essential thrombocythemia : prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005 ; 165 : 2651-8.
PubMed
3) Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis : a meta-analysis. Blood. 2012 ; 120 : 4921-8.
PubMed
4) Cortelazzo S, Finazzi G, Barbui T, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 ; 332 : 1132-6.
 
5) Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013 ; 122 : 2176-84.
PubMed
6) Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome : data from an international registry. Thromb Haemost. 2000 ; 84 : 345-9.
 
7) Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017 ; 129 : 680-92.
PubMed
8) Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012 ; 120 : 5128-33.
PubMed
9) Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia : 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 ; 95 : 1599-613.
PubMed
10) Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 ; 368 : 22-33.
PubMed
11) Foucar CE, Stein BL. JAK2 V617F mutation testing in patients presenting with hepatic and portal vein thrombosis. JAMA. 2017 ; 317 : 2228-9.
PubMed
P.590 掲載の参考文献
1) 広畑俊成. ループス精神病の分類基準. In : 橋本博史, 編. 厚生労働科学免疫アレルギー疾患予防・治療研究事業 免疫疾患の合併症とその治療法に関する研究「診療ガイドライン」. 厚生労働省 ; 2005. p.8-13.
 
2) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295-306.
 
3) ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and classification and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 ; 42 : 599-608.
 
4) Hirohata S, Kanai Y, Mitsuo A, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009 ; 28 : 1319-23.
PubMed
5) Arinuma Y, Hirohata S. Clinical features. In : Hirohata S, editor. Neuropsychiatric systemic lupus erythematosus. Cham : Springer International Publishing AG ; 2018. p.59-76.
 
6) Hirohata S. Immunopathology of neuropsychiatric systemic lupus erythematosus. In : Hirohata S, Editor. Neuropsychiatric systemic lupus erythematosus. Cham : Springer International Publishing AG ; 2018. p.29-42.
 
7) Sciascia S, Sanna G, Murru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014 ; 111 : 354-64.
PubMed
8) Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria, Ann Rheum Dis. 2023 ; 82 : 1258-70.
PubMed
9) Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005 ; 64 : 1205-9.
PubMed
P.596 掲載の参考文献
1) II. リンパ腫. In : 日本血液学会, 編. 造血器腫瘍診療ガイドライン (2023年版). 金原出版 ; 2023.
 
2) 日本脳腫瘍学会. 脳腫瘍診療ガイドライン 2019年版 成人脳腫瘍編 (改訂2版) 中枢神経系原発悪性リンパ腫 (PCNSL). https://www.jsn-o.com/guideline3/CQ/general3.html (最終閲覧 : 2024年2月5日)
 
3) 滑川道人. 中枢神経系における悪性リンパ腫 : Overview. Brain Nerve. 2014 ; 66 : 907-16.
 
4) 滑川道人, 中野今治. 血管内リンパ腫の診断-ランダム皮膚生検の有用性-. Brain Nerve. 2011 ; 63 : 451-8.
 
5) Natkunam Y, Gratzinger D, Chadburn A, et al. Immunodeficiency-associated lymphoproliferative disorders : time for reappraisal? Blood. 2018 ; 132 : 1871-8.
PubMed
6) 国立がん研究センターがん対策情報センター がん情報サービス. がん種別統計情報 悪性リンパ腫. https://ganjoho.jp/reg_stat/statistics/stat/cancer/25_ml.html (最終閲覧 : 2024年2月5日)
 
7) Cheson BD, Fisher RI, Barrington SF, et al. Recommendation for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification. J Clin Oncol. 2014 ; 32 : 3059-68.
PubMed
8) International non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993 ; 329 : 987-94.
 
9) Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 ; 123 : 837-42.
PubMed
10) Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011 ; 12 : 1258-66.
PubMed
11) McCann KJ, Ashton-Key M, Smith K, et al. Primary central nervous system lymphoma : tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood. 2009 ; 113 : 4677-80.
PubMed
12) Venetz D, Ponzoni M, Schiraldi M, et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma : T-cell infiltration and positioning of malignant B cells. Int J Cancer. 2010 ; 127 : 2300-12.
PubMed
13) Grupka NL, Seinfeld J, Ryder J, et al. Secondary central nervous system involvement by follicular lymphoma : case report and review of the literature. Surg Neurol. 2006 ; 65 : 590-4.
PubMed
14) Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016 ; 30 : 668-81.
PubMed
15) Morad G, Moses MA. Brainwashed by extracellular vesicles : the role of extracellular vesicles in primary and metastatic brain tumour microenvironment. J Extracell Vesicles. 2019 ; 8 : 1627164.
PubMed
16) Iliff JJ, Lee H, Yu M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest. 2013 ; 123 : 1299-309.
 
17) Kumaria A. Insight in primary central nervous system lymphoma : a role for glymphatics? Brain Tumor Pathol. 2021 ; 38 ; 290-1.
PubMed
18) Lin LP, Su S, Hou W, et al. Gymphatic system dysfunction in pediatric acute lymphoblastic leukemia without clinically diagnosed central nervous system infiltration : a novel DTI-ALPS method. Eur Radiol. 2023 ; 33 : 3726-34.
PubMed
19) The Committee of Brain Tumor Registry of Japan. Report of brain Tumor registry of Japan (2005-2008) 14th edition. Neurol Med Chi (r Tokyo). 2017 ; 57 (Suppl 1) : 9-102.
 
20) Provencher S, Ferlay C, Alaoui-Slimani K, et al. Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma : A case series. Hematol Oncol. 2011 ; 29 : 10-6.
PubMed
21) Rubenstein JL. Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 ; 121 : 745-51.
 
22) Sasaki N, Kobayashi K, Saito K, et al. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high dose methotrexate monotherapy. Jpn J Clin Oncol. 2020 ; 50 : 999-1008.
PubMed
23) Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008 ; 93 : 147-8.
PubMed
24) Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 ; 125 : 1403-10.
PubMed
25) Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger : Results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019 ; 37 : 823-33.
 
26) Miyao K, Yokota H, Sakemura RL. Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma? Front Oncol. 2023 ; 12 : 1082235.
 
P.603 掲載の参考文献
1) Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. 3rd. ed. Cephalalgia. 2018 ; 38 : 102-4.
 
2) 嘉山孝正, 監修. 日本医療研究開発機構 障害者対策総合研究開発事業 脳脊髄液減少症の非典型例及び小児例の診断・治療法開拓に関する研究班, 編集. 脳脊髄液漏出症診断指針. 東京 : 中外医学社 ; 2019.
 
3) Mokri B. Spontaneous low pressure, low CSF volume headache : spontaneous CSF leaks. Headache. 2013 ; 53 : 1034-53.
PubMed
4) Schaltenbrand G. Neuere anschauungen zur pathophysiologie der liquorzirkulation. Zbl neurochir. 1938 ; 3 : 290-5.
 
5) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988 ; 8 (Suppl 7) : 1-9.
 
6) Mokri B. Spontaneous cerebrospinal fluid leaks : from intracranial hypotention to cerebrospinal fluid hypovolemia-evaluation of a concept. Mayo Clinic Proc. 1999 ; 4 : 1113-23.
 
7) Huntoon MA, Watson JC. Intracranial hypotention following motor vehicle accident : An overlooked cause of posttraumatic head and neck pain? Pain Practice. 2007 ; 7 : 47-52.
 
8) Osborn AC, Hedlund CL. Hydrocephalus and CSF disorders. In : Osborn AC, editor. Osborn's Brain. 2nd. ed. Chap 34. Salt Lake City : Elsevier ; 2017. p.1119-55.
 
9) Mokri B. Headache caused by decreased intracranial pressure : diagnosis and management. Curr Opin Neurol. 2003 ; 16 : 319-26.
PubMed
10) Horton JC, Fishman RA. Neurovisual findings in the syndrome of spontaneous intracranial hypotension from dural cerebrospinal fluid leak. Ophtalmology. 1994 ; 102 : 244-31.
 
11) Warner GT. Spontaneous intracranial hypotension causing a partial third nerve palsy : a novel observation. Cephalalgia. 2002 ; 2 : 622-823.
 
12) Schievink WI. Misdiagnosis of spontaneous intracranial hypotension. Arch Neurol. 2003 ; 60 : 1713-8.
PubMed
13) Schievink WI, Morreale VA, Atkinson JL, et al. Surgical treatment of spontaneous spinal cerebrospinal fluid leaks. J Neurosurg. 1998 ; 88 : 243-6.
 
14) Portier F, de Minteguiaga C, Racy E, et al. Spontaneous intracranial hypotension : a rare cause of labyrinthine hydrops. Ann Otol Rhinol Laryngol. 2002 ; 111 : 817-20.
PubMed
15) Pannullo SC, Reigh JB, Krol G, et al. MRI changes in intracranial hypotension. Neurology. 1993 ; 43 : 919-26.
 
16) Carrero EJ, Agusti M, Fabregas N, et al. Unilateral trigeminal and facial nerve palsies accosiated with epidural analgesia in labour. Can J Anaesth. 1998 ; 45 : 893-7.
 
17) Bloch J, Regli L. Brain stem and cerebellar dysfunction after lumbar spinal fluid drainage : case report. J Neurol Soci. 2003 ; 31 : 992-4.
 
18) Schievink WI, Tourje T. Intracranial hypotension without meningeal enhancement on magnetic resonance imaging. Case report. J Neurosurg. 2000 ; 92 : 475-7.
 
19) Beck CE, Rizk NW, Kiger LT, et al. Intracranial hypotension presenting with severe encephalopathy. Case report. J Neurosurg. 1998 ; 89 : 470-3.
PubMed
20) Pakiam AS, Lee C, Lang AE. Intracranial hypotension with parkinsonism, ataxia, and bulbar weakness. Arch Neurok. 1999 ; 56 : 869-72.
PubMed
21) Ferrante E, Savino A, Brioschi A, et al. Transient oculomotor cranial nerve palsy in spontaneous intracranial hypotension. J Neurosurg Sci. 1998 ; 42 : 177-9.
PubMed
22) Hong M, Shah GV, Adams KM, et al. Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Neurology. 2020 ; 58 : 1285-7.
 
23) Peng PW. Intracranial hypotension with severe neurological symptoms resolved by epiduralblood patch. Can J Neurol Sci. 2004 ; 31 : 569-71.
PubMed
24) Albayram S, Wasserman BA, Yousem DM, et al. Intracranial hypotension as a cause of radiculopathy from cervical epidural venous engorgement : case report. Am J Neuroradiol. 2002 ; 23 : 618-21.
PubMed
25) Yamamoto M, Suehiro T, Nakata H, et al. Primary low cerebrospinal fluid pressure syndrome associated with galactorrhea. Intern Med. 1993 ; 32 : 228-31.
PubMed
26) Messori A, Simonetti BF, Regnicolo L, et al. Spontaneous intracranial hypotension : the value of brain measurements in diagnosis by MRI. Neuroradiology. 2001 ; 43 : 453-61.
PubMed
27) Kranz PG, Amrhein TJ, Choudhury KR, et al. Time-dependent changes in dural enhancement associated with spontaneous intracranial hypotension. AJR Am J Roentgenol. 2016 ; 207 : 1283-7.
PubMed
28) Kobayashi M, Nanri K, Oba H, et al. Superficial siderosis with cerebrospinal fluid leakage. Neurol Clin Neurosci. 2013 ; 1 : 87.
 
29) Starling A, Hernandesz F, hoxworth JM, et al. Sensitivity of MRI of the spine compared wuth CT myelography in orthostatic headachewith CSF leak. Neurology. 2009 ; 73 : 1892-8.
 
30) Hosoya T, Hatazawa J, Sato S, et al. Floating dural sac sign is a sensitive magnetic Resonance imaging finding of spinal cerebrospinal fluid leakage. Neurol Med Chir (Tokyo). 2013 ; 53 : 207-12.
PubMed
31) 村上友太, 齋藤清, 高橋浩一, 他. 髄液バイオマーカーとしての "脳型" トランスフェリン. 自律神経. 2019 ; 56 : 109-17.
 

書評

最近チェックした商品履歴

Loading...